| Excerpt | Reference |
|---|
| "A total of 77 patients with cancer of the head and neck area were treated with five different drug combination regimens." | ( Byers, RM; Gard, DA; Goepfert, H; Guillamondegui, OM; Holoye, PY; Jesse, RH, 1978) |
| "Forty patients with advanced head and neck cancer were treated with combined Cis-platinum-Bleomycin chemotherapy." | ( Bhutani, R; Craft, ML; Hong, WK; Shapshay, SM; Strong, MS; Ucmakli, A; Vaughan, CW; Yamaguchi, KT, 1979) |
| "Thirty-one patients with advanced cancer of the head and neck, twenty-six of whom had failed prior irradiation, were treated with an out-patient chemotherapy regimen combining methotrexate, bleomycin, and cis-diamminedichloroplatinum (II)." | ( Kaplan, BH; Vogl, SE, 1979) |
| "The value of misonidazole in advanced head and neck cancer was examined in 3 ways and the preliminary results are reported in a randomized study with large fractions of irradiation, when misonidazole appeared to confer no advantage; whereas in previously (partially) treated patients misonidazole was possibly useful." | ( Sealy, R, 1978) |
| "Ffty-three patients with head and neck cancer tested before radiation treatment to determine numbers of blood lymphocytes and immunologic responses to mitogens of lymphocytes in whole-blood cultures had mean values that were 19% to 26% less than values for healthy individuals." | ( Ellis, HN; Griffiths, CM; Jenkins, VK; Olson, MH; Perry, RR; Ray, P, 1976) |
| "The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy." | ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "34 patients with head and neck cancer were treated with carboplatin and radiation therapy." | ( Djuric, LJ; Jeremic, B; Mijatovic, LJ; Zivic, DJ, 1992) |
| "Forty Stage IV head and neck cancer patients were entered on a multimodality trial of induction chemotherapy (cisplatin + infusional 5-fluorouracil), surgery, and radiation." | ( Ashayeri, E; Gumbs, RV; Myers, EM; Pressoir, R; White, RM, 1992) |
| "A cohort of 26 patients with head and neck cancer of all histologies were entered into a broad phase I study investigating simultaneous radiation therapy, 5-FU (with or without leucovorin), HU, and infusional cisplatin administered on an alternate-week schedule." | ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "As in the early phase II study for head and neck cancers, 254-S was administered at 100 mg/m2 by 60 min intravenous drip infusion, repeated at least twice at 4-week intervals." | ( Hayasaki, K; Horiuchi, M; Inuyama, Y; Komiyama, S; Miyake, H; Ota, K, 1992) |
| "Of the ten head and neck cancer patients, five were found to have inappropriately low SIE levels before therapy, and two additional patients had a decrease of SIE levels during therapy, in one patient to an abnormally low level." | ( Goldwasser, E; Smith, DH; Vokes, EE, 1991) |
| "Effective treatment of head and neck cancer with biologic response modifiers may be benefitted by an understanding of in vivo factors capable of modulating the lymphokine-activated killer (LAK) cell phenomenon." | ( Buchsbaum, RM; Clayman, GL; Lavedan, P; Liu, FJ; Savage, HE; Schantz, SP; Taylor, DL; Trujillo, JM, 1991) |
| "Chemotherapy for head and neck cancer has made great progress after CDDP was introduced at the clinical level." | ( Fujii, M; Kawasaki, K, 1991) |
| "Eighty patients with Stage III and IV head and neck cancer were treated with a four-drug regimen consisting of bleomycin, vincristine, methotrexate, and mitomycin-C (BOMM regimen)." | ( Inuyama, Y; Kohno, N; Ohnuma, T; Sakurai, S, 1991) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Among studies in recurrent head and neck cancer, the most effective chemotherapy regimens appear to be variations of the program consisting of cisplatin followed by a 5-day infusion of 5-fluorouracil." | ( Amrein, P, 1991) |
| "We advocate routine monitoring of head and neck cancer patients for hypothyroidism after radiotherapy involving the thyroid gland and recommend levothyroxine replacement therapy for subclinical hypothyroidism." | ( Blakeslee, DB; Duncan, NO; Liening, DA; Smith, DB, 1990) |
| "Patients with head-and-neck cancers who are free of disease after local therapy remain at high risk for both recurrent and second primary tumors." | ( Byers, RM; Hong, WK; Itri, LM; Karp, DD; Kramer, AM; Lee, JS; Lippman, SM; Lotan, R; Peters, LJ; Schantz, SP, 1990) |
| "Four patients with advanced recurrent head and neck cancer were treated with surgical resection and IORT without any acute or subacute complications." | ( Friedman, C; Johnson, P; Kies, M; Mittal, BB; Pelzer, H; Sisson, GA; Tsao, CS; Ward, WF, 1990) |
| "Eleven patients with head and neck cancer (ten men, one woman; mean age, 65 years) (larynx, six; oropharynx, two; tongue, one; skin, one; thyroid, one) with regional lymph node enlargements either in contiguity or firmly adherent to the vascular structures of the neck have been treated by means of external microwaves (915, 434 MHz) applicators." | ( Airoldi, M; Brossa, PC; D'Alberto, M; Gabriele, P; Pedani, F; Ragona, R; Tseroni, V, 1990) |
| "Nearly 50% of head and neck cancers and two-thirds of patients with esophageal cancer generally present late for initial treatment." | ( Advani, SH; Desai, PB; Dinshaw, KA; Gopal, R; Pinto, JM; Saikia, TK; Sharma, S; Swaroop, VS; Vyas, JJ, 1985) |
| "In patients with locally advanced head and neck cancer, the results of standard definitive treatments of surgery, radiotherapy, or both were disappointing." | ( Ahmad, K; Al-Sarraf, M; Crissman, J; Ensley, JF; Jacobs, JR; Kish, J; Weaver, A, 1986) |
| "Ninety-three patients with head and neck cancer were treated with combined cisplatin-peplomycin chemotherapy (CP therapy)." | ( Fujii, M; Hosoda, H; Inuyama, Y; Kohno, N; Saito, S; Takaoka, T; Tanaka, J, 1986) |
| "In selected patients with advanced head and neck cancer interstitial radiotherapy with Ir-192 can be used as a palliative treatment." | ( Dobrowsky, W; Kärcher, H; Pavelka, R; Schmid, AP; Vinzenz, K, 1987) |
| "Seventy patients with stage IV head and neck cancer were treated by two courses of induction chemotherapy followed by surgery plus postoperative irradiation (7) or radical radiotherapy (62)." | ( Arellano, A; Farrus, B; Galiana, R; Hernandez, M; Pera, J; Villá, S; Villar, A, 1987) |
| "We treated 94 patients with advanced head and neck cancer with a combined-modality protocol that included induction chemotherapy followed by surgery with and without radiotherapy." | ( Loré, JM; Spaulding, MB; Sundquist, N, 1989) |
| "Results of chemotherapy in head and neck cancers are reported with a regimen of cisplatinum, bleomycin and methotrexate." | ( Deitmer, T; Urbanitz, D, 1988) |
| "Forty-five patients with epidermoid cancer of the head and neck were either treated with cisplatin and bleomycin (DDP-BLM) or with vincristine, bleomycin and methotrexate (VBM) as neoadjuvant chemotherapy before radical radiation therapy (XRT)." | ( Amichetti, M; Valentini, A, 1989) |
| "And our data are presented in head and neck cancer with multi-drug chemotherapy containing cisplatin." | ( Asano, K; Kagami, Y; Narimatsu, N; Nishio, M; Sanbe, S; Somekawa, Y, 1989) |
| "Fifty ambulatory patients with head and neck cancer treated by definitive radiation therapy at the Fox Chase Cancer Center were prospectively studied to determine the effect of oral nutritional supplements on both nutritional status and treatment response." | ( Arnold, C; Richter, MP, 1989) |
| "Recent data from the DAHANCA (Danish Head and Neck Cancer) 2 study implies a positive effect of high hemoglobin concentration in concert with misonidazole for the treatment of head and neck cancers by radiotherapy." | ( Cooper, JS; Davis, LW; Fazekas, JT; Marcial, V; Scott, C; Wasserman, T, 1989) |
| "In a prospective study of squamous head and neck cancer, the pretreatment peripheral blood of 125 patients was examined for lymphocyte subclass and in vitro immunologic function." | ( Brantley, BA; Cole, TB; Crocker, IR; Fisher, SR; Huang, AT; Mold, NG; Wallman, MJ, 1987) |
| "Thirty-one patients with head and neck cancer were administered pretreatment induction chemotherapy (so-called neo-adjuvant chemotherapy) consisting of a UFT and ADM combination." | ( Hyo, N; Imura, S; Kishimoto, M; Kumoi, T; Ogasawara, H; Toda, K, 1987) |
| "In advanced inoperable head and neck cancer radiotherapy alone is unsatisfying." | ( Hartenstein, R; Kastenbauer, ER; Wendt, TG, 1988) |
| "Sixteen patients with head and neck cancer were administered lysozyme chloride for more than 6 months in combination with chemotherapy, irradiation and/or surgery." | ( Inouye, K, 1987) |
| "Nineteen patients with locally advanced head and neck cancer were treated from November 1983 to January 1986 with standard loco-regional Radiotherapy: 2 Gy for 5 days/week up to a total dose of 70 Gy and simultaneous Cisplatinum 20 mg/m2 weekly." | ( Barni, S; Colombo, A; Crispino, S; Frigerio, F; Lissoni, P; Mazzola, P; Nava, S; Paolorossi, F; Placa, F; Tancini, G, 1987) |
| "Occasionally head and neck cancer patients treated with high-energy X rays and gamma rays have titanium metal dental implants in their maxillae or mandibles." | ( Boyer, AL; Jacob, RF; Kramer, DC; Mian, TA; Van Putten, MC, 1987) |
| "Treatment of the head and neck cancer has surprisingly developed in the last decade." | ( Komiyama, S; Kudo, S; Kuwano, N; Yanagita, T, 1986) |
| "Thirty-eight cases of head and neck cancer treated with cis-diamminedichloroplatinum (II) (CDDP) with/without the combination of Peplomycin (PEP) from 1982 to 1985 were evaluated." | ( Harada, Y; Nakata, M; Takebayashi, S; Yajin, K, 1986) |
| "Thirty-one patients with advanced head and neck cancer were treated with 4'-epidoxorubicin." | ( Bosl, GJ; Howard, J; Magee, MJ; Wittes, RE, 1985) |
| "Seventy-five cases of head and neck cancer except of maxillary sinus, 27 cases of mesopharyngeal cancer, 6 cases of oral cancer, 9 cases of thyroid cancer and 9 cases of the other cancer, were treated with this multi-disciplinary treatment and the results were evaluated in this series." | ( Maehara, Y; Makino, S; Matsuura, S; Miyama, J; Nakamura, Y; Sakaino, K; Satake, B; Shimizu, R, 1985) |
| "In seven patients with head and neck cancer, two-route-infusion chemotherapy using cisplatin (CDDP) and sodium thiosulfate (STS) was performed and their pharmacokinetics were studied." | ( Ikeda, K, 1986) |
| "Sixty-six patients with advanced head and neck cancer 57 of whom had failed to respond to prior irradiation, were treated according to two protocols." | ( Asselin, B; Bataini, JP; Brugère, J; Garcia-Giralt, E; Jaulerry, M; Jouve, M; Palangie, T; Pouillart, P, 1980) |
| "Forty-six patients with advanced cancer of the head and neck, 42 of whom had failed conventional radiotherapy or surgical excision, or both, were treated on an outpatient basis with a regimen consisting of bleomycin, methotrexate and cis-diamminedichloroplatinum II." | ( Chiuten, D; Greenwald, E; Kaplan, BH; Vogl, SE, 1980) |
| "Twenty-six patients with advanced head and neck cancer, 22 of whom had failed prior surgery and/or radiotherapy, were treated with a combination regimen of cis-diamminedichloroplatinum II, bleomycin, and methotrexate." | ( Alberts, DS; Coulthard, S; Dana, B; Griffin, CB; Manning, M; Mattox, DE; Myers, JW; Von Hoff, DD, 1981) |
| "Seventy two head and neck cancers have been treated with a combination of Cis-DDP (20 mg/m2/day) and bleomycin (6 mg/m2/day, 24 hours infusion) given for 5 days 3 courses every 3 weeks in preoperative cases and for 6 days (4 courses every 3 weeks) in non preoperative cases." | ( Aguilera, J; Breau, JL; Frachet, B; Israel, L; Soudant, J; Strunski, V, 1982) |
| "Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy." | ( Banhidy, F; Borsos, G; Crooke, ST; D'Aoust, JC; Eckhardt, S; Issell, BF, 1982) |
| "Twenty-two patients with advanced cancer of the head and neck where treated with a combination of bleomycin, methotrexate, and cisplatin." | ( Cohen, Y; Kuten, A; Robinson, E; Zidan, J, 1983) |
| "Regional treatment of advanced head and neck cancer by intra-arterial infusion has been tried for several years." | ( Borms, M; Huys, J; Troch, M, 1983) |
| "52 patients with epidermoid cancer of the head and neck region were either treated with cis-DDP and bleomycin (arm A) or with methotrexate and vindesine (arm B)." | ( Beyer, JH; Borghardt, J; Caliebe, W; Gerhartz, H; Hofmann, J; Kastenbauer, E; Lissers, R; Nagel, GA; Rudert, H; Scherpe, A; Schneider, B; Schröder, M; Schroeder, M; von Heyden, HW; Westerhausen, M, 1983) |
| "Twenty-eight patients with head and neck cancer were treated with a combination of bleomycin, cyclophosphamide, adriamycin, and methotrexate (BEAM regimen), consisting cyclophosphamide 600 mg/body and adriamycin 40 mg/body on day 1, bleomycin 15 mg/body and methotrexate 20 mg/body on days 1 and 5." | ( Inoue, A; Kasai, N; Noguchi, A; Uchida, M, 1983) |
| "Before loco regional treatment for head and neck cancer forty eight patients received one or the other of the following combined chemotherapy regimens: Regimen A (28 patients): high dosage methotrexate, bleomycin, cis-platin; regimen B (20 patients): common dosage methotrexate, bleomycin, hydroxyurea, vincristin." | ( Brun, B; Feuillade, F; Grellet, M; Langlois, A; Lebourgeois, JP; Lelièvre, G; Martin, M; Mazeron, JJ; Peynegre, R; Pierquin, B, 1984) |
| "Fifty-eight patients with advanced head and neck cancer were entered into a randomised trial comparing chemotherapy (DDP + bleomycin) alone, multiple daily fractionated radiation therapy, and multimodality therapy consisting of chemotherapy plus multiple fractionated radiation therapy." | ( Bezwoda, WR; Browde, S; de Moor, NG; Derman, DP; Nissenbaum, M, 1984) |
| "Head and neck cancer patients received treatment to 114 sites with a complete response (CR) in 28, partial response (PR) in 42, stable disease (SD) in three, and no response (NR) in 34, and an undetermined response in seven." | ( Baghdassarian, R; Berns, MW; Coffey, J; Mason, GR; Nahabedian, MY; Wile, AG, 1984) |
| "In 30 patients with head and neck cancer, OK-432 was administered singly or combined with IFN-alpha at intervals of 2 weeks, and the amount of IFN in the blood induced by OK-432 was compared." | ( Go, K; Konishi, K; Morisaki, N; Nakai, Y; Sugita, M; Sugiyama, M, 1984) |
| "37 evaluable patients with relapsed head and neck cancer received as treatment Cisplatin alone (18 patients) or Cisplatin + Adriamycin (19 patients)." | ( de Caralt, M; Farrus, B; Giner, P; Sedano, E; Serradell, J; Villar, A, 1981) |
| "Eighty-nine poor risk head and neck cancer patients, who had received extensive prior therapy with surgery, radiation, and/or multiple drugs were studied." | ( Fletcher, WS; Lehane, D; McCracken, JD; Panettiere, FJ; Rivkin, S; Stephens, R, 1980) |
| "Eighty-two patients with advanced cancer of the head and neck have been treated with sequential administration of methotrexate and cisplatin." | ( Chandler, JR; Tejada, FJ, 1981) |
| "Thirty-four patients with advanced head and neck cancer were treated by synchronous radiotherapy and methotrexate (MTX) (100 mg/m2)." | ( Askill, CS; Hunter, RD; Pointon, RC; Wilkinson, PM, 1981) |
| "The treatment of head and neck cancer patients with persistent severe pain often requires a multidisciplinary approach." | ( McCann, CF; Scott, RM; Shapshay, SM; Stoelting, I, 1980) |
| "A group of 23 patients with advanced head and neck cancer were treated with highly selective intra-arterial (IA) cisplatin 150 mg/m2 delivered rapidly through microcatheters." | ( Barton, R; Blommaert, fA; den Engelse, L; Hanchett, C; Heath, DD; Howell, SB; Los, G; Robbins, KT; Vicario, D; Weisman, R, 1995) |
| "The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck." | ( Cappelaere, P; Clavel, M; Clerico, M; Cognetti, F; de Mulder, PH; Schornagel, JH; Tueni, EA; Vermorken, JB; Verweij, J; Wildiers, J, 1994) |
| "Intraarterial drug therapy for head and neck cancer has been used for more than 30 years." | ( Eckardt, A; Kelber, A, 1994) |
| "Intra-arterial drug therapy for head and neck cancer has been used for over 30 years." | ( Eckardt, A; Kelber, A; Pytlik, C, 1995) |
| "Forty-two patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively and clinical value of this treatment was assessed." | ( Itokazu, T; Kochi, A; Koja, S; Maeda, H; Maeshiro, N; Matsumura, J; Noda, Y; Yasuda, S, 1995) |
| "Fifteen patients with head and neck cancer (13 with squamous cell carcinoma, 1 with adenocystic carcinoma, and 1 with paranasal plasmocytoma) underwent a PET study with [11C]-methionine both before and after preoperative radiotherapy to the total tumor dose of 61-73 Gy." | ( Grénman, R; Joensuu, H; Lehikoinen, P; Leskinen-Kallio, S; Lindholm, P; Någren, K; Ruotsalainen, U; Teräs, M, 1995) |
| "The mainstay of treatment for head and neck cancer patients with recurrent disease has been chemotherapy with cisplatin/5-fluorouracil or methotrexate." | ( Forastiere, AA, 1994) |
| "Fifty patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively." | ( Esu, H; Itokazu, T; Kamiya, S; Kanazawa, T; Koja, S; Maeshiro, N; Noda, Y; Simoji, Y; Yamauchi, M, 1994) |
| "Head and neck cancer is mostly curable in the early stages by either surgery or radiotherapy alone, but the control rate for advanced stages is low, even with combined surgery and postoperative radiotherapy." | ( Hsu, CY; Jan, JS; Lin, JC, 1994) |
| "Metastatic squamous cell head and neck cancer was treated in four patients with low-dose cyclophosphamide (to reduce suppressor T-cell activity), indomethacin (to reduce prostaglandins that mediate macrophage-induced immune suppression), zinc (to augment T-cell function via thymulin), and mixed natural interleukins perilymphatically in the neck (as adjuvant for tumor antigen in the region)." | ( Baekey, P; Endicott, J; Hadden, EM; Hadden, JW; Skipper, P, 1994) |
| "Cohort study of patients with head and neck cancer receiving cisplatin chemotherapy who underwent audiometric testing." | ( Blakley, BW; Gupta, AK; Myers, SF; Schwan, S, 1994) |
| "Forty-two patients with head and neck cancer who agreed to participate underwent at least three serial treatments with high-dose cisplatin therapy." | ( Blakley, BW; Gupta, AK; Myers, SF; Schwan, S, 1994) |
| "A total of 36 patients with advanced head and neck cancer were treated with radical radiotherapy and weekly concomitant cisplatinum chemotherapy." | ( Cheesman, AD; Glaser, MG; Leslie, MD; Newlands, ES; O'Reilly, SM, 1993) |
| "Twenty-two disease-free head and neck cancer patients were studied, 1 to 3 years after multimodal treatment, to determine if changes in serum ionized calcium levels or thyroid function were present." | ( Carroll, WR; Esclamado, R; Sassler, AM; Talmi, YP; Wolf, GT, 1993) |
| "Patients with head and neck cancer who continue to smoke during radiation therapy have lower rates of response and survival than patients who do not smoke during radiation therapy." | ( Browman, GP; Hodson, I; Levine, MN; McAlpine, L; Russell, R; Sathya, J; Skingley, P; Wong, G, 1993) |
| "Five patients with head and neck cancer underwent two PET studies prior to cancer therapy, first in the fasting state and then 2-5 days later after oral glucose loading." | ( Bergman, J; Joensuu, H; Leskinen-Kallio, S; Lindholm, P; Minn, H; Ruotsalainen, U, 1993) |
| "A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i." | ( Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J, 1993) |
| "Much of the early clinical work in head and neck cancer involved treatment of patients with advanced, recurrent disease who had not responded to conventional therapy." | ( DeLaney, TF; Lebovics, RS, 1993) |
| "Regional chemotherapy for head and neck cancers is effective, but the intra-arterial catheter is not without problems." | ( Choi, TK; Ho, CM; Lam, KH; Lam, LK; Wei, WI, 1993) |
| "Advanced-stage squamous cell cancer of the head and neck remains a difficult therapeutic dilemma despite aggressive use of surgery and radiation therapy." | ( Spencer, S; Wheeler, RH, 1995) |
| "Recurrent cancer of the head and neck after primary therapy is almost always fatal." | ( Benedetti, J; Ensley, J; Hussain, M; Rodriguez, GI; Schuller, D; Smith, RE, 1995) |
| "Stage IV inoperable head and neck cancer has a 2-year mortality rate of greater than 70% when treated with conventional radiotherapy." | ( Benninger, MS; Boyd, SB; Carlson, ER; Doyle, TJ; Dragovic, J; Jacobsen, GR; Nichols, RD; Tilchen, EJ, 1995) |
| "Second primary cancers often occur in head and neck cancer patients successfully treated by radiation therapy." | ( Bairati, I; Brochet, F; Gélinas, M; Mâsse, B; Meyer, F; Nabid, A; Roy, J; Têtu, B, 1996) |
| "Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month multicenter maintenance study to evaluate the long-term safety and efficacy of oral pilocarpine for the treatment of radiation-induced xerostomia." | ( Jacobs, CD; van der Pas, M, 1996) |
| "Hyperbaric oxygen (HBO) trials for head and neck cancer, conducted in the early 1970s, demonstrated that HBO improved local control and survival rates in patients with head and neck cancer receiving radiotherapy (RT)." | ( Giuliano, J; Lee, DJ; Moini, M; Westra, WH, 1996) |
| "The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease." | ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997) |
| "during radiotherapy for head and neck cancer and 3 months thereafter was associated with significantly less subjective xerostomia than that reported by a similar cohort of patients who had not received pilocarpine." | ( Juillard, GF; Mark, RJ; Tran, LM; Zimmerman, RP, 1997) |
| "Results of chemotherapy for head and neck cancer are now improving owing to the development of concomitant use of chemotherapeutic agents such as cisplatin or peplomycin." | ( Kakimoto, S; Kawamoto, K; Kumazawa, H; Tachikawa, T; Wada, Y; Yamashita, T, 1996) |
| "The smoking habits of head and neck cancer patients were evaluated using a questionnaire administered at two tertiary head and neck cancer centers." | ( DiNardo, LJ; Oliver, DS; Vander Ark, W, 1997) |
| "In 42 patients with head and neck cancer, postoperative radiation treatment or radiation combined with chemotherapy was performed." | ( Adamietz, IA; Böttcher, HD; Heyd, R; Knecht, R; Mose, S; Saran, F; Thilmann, C, 1997) |
| "The treatment of head and neck cancer has traditionally consisted of surgery with postoperative radiation therapy." | ( Vokes, EE, 1997) |
| "Patients with Stage III/IV head and neck cancer were treated in this multicenter Phase II Study with 1." | ( Clark, J; Glicksman, AS; Landmann, C; Liu, L; Lohri, A; Probst, R; Slotman, G; Wanebo, HJ; Zhu, TC, 1997) |
| "Patients with head and neck cancers considered curable with local treatment modalities were excluded." | ( Greco, FA; Hainsworth, JD; Meluch, AA, 1997) |
| "High uptake of FDG in untreated head and neck cancer is associated with advanced disease, and may portend poor survival." | ( Bergman, J; Eronen, E; Grénman, R; Haaparanta, M; Joensuu, H; Klemi, PJ; Lapela, M; Leskinen, S; Lindholm, P; Minn, H, 1997) |
| "The first-line chemotherapy for head and neck cancer is reported to be the combination of CDDP and 5-FU." | ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1998) |
| "Organ-preservation programs in head and neck cancer result in improved QOL and swallowing 6 months after treatment." | ( Madasu, R; Martin, A; Murry, T; Robbins, KT, 1998) |
| "Patients with head and neck cancer received radiotherapy (2 Gy/day 5 days a week up to 60 Gy) with carboplatin 70 mg/m2 on days 1-5 and 21-25 inclusive." | ( Büntzel, J; Glatzel, M; Küttner, K; Schuth, J, 1998) |
| "Patients with locoregionally advanced head and neck cancer were treated either with RT alone (arm A) or simultaneous RT plus CT (RCT; arm B)." | ( Aydin, H; Grabenbauer, GG; Iro, H; Popella, C; Rödel, CM; Rohloff, R; Schalhorn, A; Thiel, HJ; Wendt, TG; Wustrow, TP, 1998) |
| "Forty-seven patients with advanced head and neck cancer treated with a targeted chemoradiation protocol were monitored for weight and eating status before treatment and as long as 18 months after treatment." | ( Kumar, P; Murry, T; Newman, LA; Robbins, KT; Samant, S; Schwiezer, V; Vieira, F; Woodson, G, 1998) |
| "Patients with advanced head and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice daily, for a total of 7500 cGy." | ( Albers, ME; Brizel, DM; Fisher, SR; George, SL; Hars, V; Huang, AT; Prosnitz, LR; Richtsmeier, WJ; Scher, RL, 1998) |
| "Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone." | ( Albers, ME; Brizel, DM; Fisher, SR; George, SL; Hars, V; Huang, AT; Prosnitz, LR; Richtsmeier, WJ; Scher, RL, 1998) |
| "One hundred twenty-two head and neck cancer patients were randomly assigned to receive induction chemotherapy with cisplatin (100 mg/m2, day 1) and 5FU (96-h continuous infusion), either at standard dose (St-arm; 4 g/m2) or at a dose adjusted according to the 5FU area under the curve (AUC0-48h; PK-arm)." | ( Barberi-Heyob, M; Campion, L; Conroy, T; Etienne, MC; Fety, R; Hardouin, A; Merlin, JL; Milano, G; Perrocheau, G; Rivière, A; Rolland, F, 1998) |
| "The subjects all had head or neck cancer and had received radiation therapy, but no more recently than three months before taking part in the study." | ( Meyerowitz, C; Watson, GE, 1998) |
| "Fifty patients with cancer of the head and neck and the pelvis were randomized before radiotherapy to different rhEPO treatments (none, 3 x 150 U/kg per week i." | ( Barke, A; Frommhold, H; Guttenberger, R; Henke, M; Pajonk, F; Pötter, R, 1999) |
| "In head-and-neck cancer, chemosensitivity is inconstant, and no marker is available to predict response to treatment." | ( Beaune, P; Blons, H; Brasnu, D; Cabelguenne, A; Carnot, F; de Waziers, I; Hamelin, R; Laccourreye, O; Laurent-Puig, P, 1999) |
| "New approaches to the treatment of head and neck cancer involve delivery of the therapeutic agent by direct injection into the tumor lesions." | ( Clayman, GL; Dreiling, LK, 1999) |
| "Patients with head and neck cancer who chewed betel quid habitually seem to experience more severe chemotherapy-induced mucositis in our clinical practice." | ( Chen, IH; Chen, JS; Liao, CT; Su, CL; Wang, CH; Wang, HM, 1999) |
| "In head and neck cancer, we have found that gemcitabine doses far below the maximum tolerated dose for the drug when used alone significantly potentiate the toxicity of treatment." | ( Eisbruch, A; Fields, MT; Lawrence, TS; McGinn, CJ; Shewach, DS, 1999) |
| "Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)." | ( Altmann, S; Hoffmanns, H, 1999) |
| "Chemotherapy in head and neck cancer can be given in metastatic disease at presentation, in locally far advanced disease not amendable for curative treatment with surgery and/or radiotherapy, in the neo-adjuvant setting, in recurrent disease after previous surgery and radiotherapy and either concurrent or alternating with radiotherapy." | ( De Mulder, PH, 1999) |
| "To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy." | ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis." | ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000) |
| "Occasionally in head and neck cancer patients treated surgically after induction chemotherapy, the histologic analysis of the excised tissue does not show evidence of viable tumor cells, a situation that the authors named "negative specimen." | ( de Juan, M; León, X; López-Pousa, A; Orús, C; Quer, M; Sancho, FJ, 2000) |
| "Forty-three patients with head and neck cancer were examined with F-18 FDG PET at least 4 months after their last course of radiation therapy (mean, 11 months)." | ( Alavi, A; Denittis, A; Li, P; Machtay, M; Mozley, PD; Smith, R; Yeh, D; Zhuang, H, 2001) |
| "For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12." | ( Kitahara, S; Kohno, N, 2001) |
| "Head-and-neck cancer patients, when scheduled for treatment by external beam radiation therapy (EBRT), were randomized for prophylactic treatment with an oral paste containing either a placebo or a combination of the antibiotics polymyxin E, tobramycin, and amphotericin B (PTA group)." | ( Gan-Teng, AM; Harms, ER; Hendriks, WD; Levendag, PC; Schmitz, PI; van der Est, H; Visch, LL; Wijers, OB; Wilims, EB, 2001) |
| "Patients with head and neck cancers can develop salivary hypofunction after radiotherapy." | ( Ferre, J; Fuster, D; Lomeña, F; Martin, F; Mateos, JJ; Navalpotro, B; Ortega, M; Pavia, J; Pons, F; Rovirosa, A; Setoain, X, 2001) |
| "56 patients with head and neck cancers underwent measurement of tumor volume (pretreatment CT scans), tumor oxygenation (pO2 histography) and serum levels of VEGF." | ( Becker, A; Dunst, J; Haensgen, G; Kuhnt, T; Lautenschläger, C; Molls, M; Stadler, P, 2001) |
| "Recommended treatment for head and neck cancer associates surgery and radiotherapy." | ( Alix, T; Bénateau, H; Crasson, F; Labbé, D; Riscala, S, 2001) |
| "One hundred and six head and neck cancer patients were treated by interstitial brachytherapy alone (n = 29) or combined with external irradiation (n = 77)." | ( Bahadur, S; Bansal, M; Deo, SV; Mohanti, BK; Prabhakar, R; Rath, GK; Shukla, NK, 2001) |
| "Patients with recurrent squamous cell cancer of the head and neck (SCH&N) are generally treated with systemic chemotherapy." | ( Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2001) |
| "A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed." | ( Ho, CM; Ho, WK; Lam, P; Wei, WI; Yuen, AP, 2001) |
| "Forty-five patients with head and neck cancers were evaluated with FDG-PET scans as well as either CT or MRI prior to treatment with definitive radiation (RT)." | ( D'Agostino, RB; Greven, KM; Harkness, BA; Keyes, JW; McGuirt, WF; Watson, NE; Williams, DW, 2001) |
| "Patients who receive radiotherapy for head and neck cancer are likely to develop painful mucositis." | ( Andersen, J; Ehrnrooth, E; Grau, C; Zachariae, R, 2001) |
| "Detection of metastatic disease in head and neck cancer patients is critical to preoperative planning, because patients with distant metastasis will not benefit from surgical therapy." | ( Lee, D; Marn, CS; Rosenthal, EL; Taylor, R; Teknos, TN, 2001) |
| "Ninety-seven patients with advanced head and neck cancers were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate (STS) from 1995 to 2000." | ( Yokoyama, J, 2002) |
| "In patients with head and neck cancer enrolled onto a prospective study of positron emission tomography (PET), pretreatment 2-[(18)F] fluoro-2- deoxy-D-glucose (FDG) uptake was evaluated as a predictor of local control and disease-free survival (DFS) after treatment by radiotherapy (RT) with or without chemotherapy." | ( Allal, AS; Allaoua, M; Dulguerov, P; El-Ghazi, el A; Haenggeli, CA; Lehmann, W; Slosman, DO, 2002) |
| "Patients with advanced squamous cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1." | ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "33 patients with head and neck cancer were administered iododeoxyuridine (IdUrd) prior to treatment and a second administration of bromodeoxyuridine (BrdUrd) prior to the fifth fraction of 2 Gy." | ( Flygare, P; Gustafsson, H; Sjöström, B; Wilson, GD; Zackrisson, B, 2002) |
| "Applications of PET in extracranial head and neck neoplasms have included evaluating patients with unknown primary lesions, detecting primary and recurrent head and neck tumors, monitoring response to radiotherapy, and evaluating the N0 neck in oral cavity carcinomas." | ( Gabalski, EC; Gona, JM; Husain, S; Myers, LL; Nabi, H; Wax, MK, 2002) |
| "These assumptions regarding head and neck cancer in patients treated with concurrent hyperfractionated radiation therapy and intraarterial supradose cisplatin (HYPERRADPLAT) have never been evaluated." | ( Arnold, SM; Regine, WF; Shane, M; Spring, PM; Valentino, J, 2002) |
| "The Meta-Analysis of Chemotherapy in Head and Neck Cancer collaborative group has suggested a survival advantage of 5% at 5 years for platin-5-fluorouracil induction chemotherapy." | ( Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S, 2002) |
| "Administration of (99m)Tc-BRU 59-21 in head and neck cancer patients appears to be safe and feasible." | ( Balm, AJ; Begg, AC; Haustermans, KM; Hoebers, FJ; Hoefnagel, CA; Janssen, HL; Nunn, AD; Olmos, AV; Sprong, D, 2002) |
| "6: Restaging of head and neck cancer with possibilities of curative treatment." | ( Borrego Dorado, I; Vázquez Albertino, R, 2002) |
| "25 patients with locally advanced head and neck cancer were treated with 4 cycles of vinorelbine (20 mg i." | ( Catalano, G; Chiesa, F; De Braud, F; De Paoli, F; De Pas, T; DePas, T; Jereczek-Fossa, BA; Krengli, M; Marrocco, E; Masci, G; Orecchia, R; Robertson, C; Vavassori, A, 2002) |
| "Comparative clinical studies of head and neck cancer have not provided good evidence, with the exception of an RCT of adjuvant chemotherapy with UFT, in the past." | ( Fujii, M, 2002) |
| "Sixty-five patients with advanced head and neck cancer underwent a definitive (53 patients) or a postoperative adjuvant (12 patients) chemoradiation treatment." | ( Arcangeli, G; Arcangeli, S; Carlini, P; Cognetti, F; Danesi, DT; De Campora, E; Giovinazzo, G; Mecozzi, A; Saracino, B, 2002) |
| "Patients diagnosed with head and neck cancer face a myriad of treatment options." | ( Gosselin, TK; Pavilonis, H, 2002) |
| "Patients undergoing radiotherapy for head and neck cancer are at increased risk of developing oral candidiasis." | ( Aktas, E; Koc, M, 2003) |
| "Adult head and neck cancer patients who were undergoing treatment with radiotherapy and/or chemotherapy, radiotherapeutic coverage of the entire oropharynx and oral cavity at least 3 cm anterior to the retromolar trigone and receiving a total dose of more than 6000 cGy and Karnofsky Performance Status (KPS) >70 were included in the study." | ( Aktas, E; Koc, M, 2003) |
| "Patients with advanced head and neck cancer were treated with primary curative radiotherapy (66 Gy in 33 fractions with five fractions per week) +/-a single injection (15 mg/m(2)) of MMC at the end of the first week of radiotherapy." | ( Abeyakoon, S; Dinshaw, KA; Grau, C; Hadjieva, T; Jabeen, K; Overgaard, J; Prakash Agarwal, J; Rab Khan, A; Tatsuzaki, H; Turkan, S; Wahid, I, 2003) |
| "The systemic therapy of head and neck cancer has gained momentum in recent years." | ( Argiris, A; Haraf, DJ; Kies, MS; Vokes, EE, 2003) |
| "Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear." | ( Andersen, E; Andersen, L; Bastholt, L; Bentzen, J; Evensen, JF; Grau, C; Hansen, HS; Hansen, O; Johansen, J; Overgaard, J; Overgaard, M; Specht, L, 2003) |
| "Twenty-nine patients with recurrent head and neck cancers were treated using intra-arterial infusion chemotherapy." | ( Kawamoto, K; Kuroiwa, T; Ochiai, N; Tajima, T; Tomita, K; Yabuuchi, H, 2003) |
| "Treatment of human head and neck cancer established as xenografts in athymic mice with immunostimulatory CpG oligodeoxynucleotides encapsulated in sterically stabilized cationic liposome [(CpG ODN)(SSCL)] and recombinant interleukin-13 Pseudomonas exotoxin (IL13-PE) significantly reduced the tumor growth followed by complete regression in most animals." | ( Conover, J; Gursel, I; Ishii, KJ; Joshi, BH; Kawakami, K; Klinman, DM; Puri, RK, 2003) |
| "In advanced head and neck cancer, an organ-sparing approach comprising radiation therapy combined with intra-arterial chemotherapy has become an important technique." | ( Fukuda, H; Itoh, M; Kubota, K; Ono, S; Qureshy, A; Yamaguchi, K; Yokoyama, J, 2004) |
| "The treatment of head and neck cancer continues to evolve." | ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003) |
| "Recent studies in the treatment of head and neck cancer suggest that combined chemoradiation is superior to radiation alone with regard to local-regional control." | ( Nabell, L; Spencer, S, 2003) |
| "Twelve patients with AJCC Stages III-IV cancer of the head and neck received CT or MRI and PET imaging before treatment with definitive radiation therapy." | ( Cappellari, JO; Geisinger, K; Greven, KM; Keyes, JW; McGuirt, WF; Rogers, JW; Watson, NE; Williams, DW, 2004) |
| "Patients with advanced cancer of the head and neck, who have exhausted other treatment options, can achieve significant clinical benefit and improvement in quality of life with mTHPC." | ( Biel, MA; D'Cruz, AK; Robinson, MH, 2004) |
| "Recurrent/metastatic head and neck cancer is an area of high, unmet treatment need." | ( Caponigro, F, 2004) |
| "Although 50-70% of head and neck cancer patients in India receive radiotherapy (RT), radiation-related acute and late morbidities and their impact on quality of life (QOL) are infrequently reported." | ( Bahadur, S; Bansal, M; Chaudhry, R; Mohanti, BK; Shah, N; Shukla, NK, 2004) |
| "One hundred forty patients with head and neck cancer treated with radical RT, concurrent chemoradiation, or postoperative RT were retrospectively studied." | ( Bahadur, S; Durga, T; Mohanti, BK; Munshi, A; Pandey, KC; Pandey, MB, 2003) |
| "Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy." | ( Beaune, P; Beauregard, J; Blons, H; Brasnu, D; Gad, S; Laccourreye, O; Laurent-Puig, P; Manière, I; Tregouet, D; Zinzindohoué, F, 2004) |
| "Among high-risk patients with resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantly improve the rates of local and regional control and disease-free survival." | ( Campbell, BH; Chao, KS; Cmelak, AJ; Cooper, JS; Ensley, JF; Forastiere, AA; Fu, KK; Jacobs, J; Kim, HE; Kish, JA; Lee, N; Machtay, M; Pajak, TF; Rotman, M; Saxman, SB; Schultz, CJ, 2004) |
| "Twenty-one patients with head-and-neck cancer underwent multitracer positron emission tomography (PET) before the start of preoperative or definitive radiotherapy (RT)." | ( Eskola, O; Grénman, R; Grönroos, T; Lehtiö, K; Minn, H; Oikonen, V; Sillanmäki, L; Viljanen, T, 2004) |
| "Thirty patients with head and neck cancer were randomly assigned to receive either zinc sulphate capsules (including 50 mg zinc) (n = 15) or placebo (n = 15) three times a day, starting on the day of the first radiotherapy fraction and continuing throughout the scheduled radiotherapy course including weekends and 6 weeks after radiotherapy." | ( Bakan, N; Ertekin, MV; Karslioğlu, I; Koç, M; Sezen, O; Taysi, S, 2004) |
| "Recent studies on polychemotherapy of head and neck cancer showed an improved remission rate on adding taxanes to the standard cytotoxic drugs cisplatin and 5-fluorouracil (5-FU)." | ( Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Peters, S; Solbach, C, 2005) |
| "Studying head and neck cancer cells treated with human lactoferrin, we observed growth arrest in three of four cell lines tested." | ( Minhas, KM; Monitto, CL; Sidransky, D; Xiao, Y, 2004) |
| "Twenty nine patients with advanced head and neck cancer were treated with curative radio(chemo)therapy." | ( Feltl, D; Hozak, P; Pala, M; Zavadova, E, 2005) |
| "In radiotherapy of head and neck cancer (HNC) and non-small cell lung cancer (NSCLC), hypoxia is known to be an important prognostic factor for long-term survival and local tumor control." | ( Bares, R; Dittmann, H; Eschmann, SM; Machulla, HJ; Paulsen, F; Reimold, M; Reischl, G; Welz, S, 2005) |
| "In patients with non-resectable head and neck cancer concomitant chemoradiotherapy is increasingly used, especially in cases of oropharyngeal and hypopharyngeal tumours." | ( de Jong, M; Jansen, P; Kerrebijn, J; Planting, A; Smith, M; Verweij, J, 2005) |
| "Several strategies in the treatment of head and neck cancers have been developed to prevent RT-induced salivary dysfunction while providing definitive oncologic therapy." | ( Hu, K; Ship, JA, 2004) |
| "This intensive treatment regimen for head and neck cancer is feasible and effective in a multi-institutional setting." | ( Cmelak, A; Fu, K; Harris, J; Kumar, P; Levine, P; McCulloch, T; Robbins, KT; Sofferman, R; Weisman, R; Weymuller, E; Wilson, W, 2005) |
| "Thirty-six patients with intact primary head and neck cancers treated with radiation therapy (RT) received PET-CT as part of treatment planning." | ( Davis, LW; Halkar, R; Howell, R; Koshy, M; Paulino, AC; Schuster, D, 2005) |
| "The hypoxia problem in head and neck cancer needs to be addressed if improvements in current treatments are to be made." | ( Balm, AJ; Begg, AC; Haustermans, KM; Janssen, HL, 2005) |
| "In head and neck cancer, it has been shown that hypoxic tumors respond poorly to therapy." | ( Boerman, OC; Bussink, J; Kaanders, JH; Peters, JP; Rijken, PF; Troost, EG; van der Kogel, AJ; van Eerd, J, 2005) |
| "In head-and-neck cancer, the value of FDG-PET for radiation treatment planning is still under investigation." | ( Grosu, AL; Jeremic, B; Molls, M; Picchio, M; Piert, M; Schratzenstaller, U; Schwaiger, M; Weber, WA; Zimmermann, FB, 2005) |
| "The growing use of PET-CT studies in head and neck cancer will certainly make a significant difference in the treatment and outcome in this disease." | ( Graham, MM; Menda, Y, 2005) |
| "Treatment of head and neck cancer could be improved and perhaps standardized if reliable markers for tumor progression and poor prognosis could be developed." | ( Bezabeh, T; Kerr, P; Nason, R; Odlum, O; Patel, R; Smith, IC; Sutherland, D, 2005) |
| "Five pediatric patients with head and neck cancers were treated with radiotherapy." | ( Anacak, Y; Haydaroglu, A; Kamer, S, 2007) |
| "Twelve head and neck cancer patients were examined by dynamic 11C-methionine PET after radiotherapy." | ( Buus, S; Grau, C; Jensen, K; Keiding, S; Mouridsen, K; Munk, OL; Rodell, A, 2006) |
| "We calculated Ccrs of 107 head and neck cancer patients since January, 2004 to August, 2005, and evaluated renal function before any treatment." | ( Horiuchi, C; Kawakami, M; Kondo, N; Masuda, Y; Matsuda, H; Mikami, Y; Nagao, J; Nishimura, G; Taguchi, T; Tsukuda, M; Yabuki, K; Yoshida, T, 2006) |
| "isolated from head and neck cancer patients treated with radiotherapy or chemotherapy to antifungal agents." | ( Zhang, WD; Zhao, M; Zhou, ZT, 2006) |
| "isolated from head and neck cancer patients treated with radiotherapy or chemotherapy was pretty high." | ( Zhang, WD; Zhao, M; Zhou, ZT, 2006) |
| "Head and neck cancer frequently presents at a late stage, leading to a poor prognosis despite optimal treatment with surgery and/or radiotherapy." | ( Alkureishi, LW; de Bree, R; Ross, GL, 2006) |
| "Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis." | ( Li, Y; Machtay, M; Wong, SJ, 2006) |
| "Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate." | ( Bonomi, M; Cabalar, ME; Castro, MA; Cerchietti, LC; Kirchuk, R; Lutteral, MA; Navigante, AH; Negretti, G; Roth, B; Sheinker, B; Uchima, P, 2006) |
| "Twelve head-and-neck cancer (HNC) patients underwent FDG and FMISO PET examinations prior to RT treatment." | ( Alber, M; Eschmann, SM; Holzner, F; Paulsen, F; Thorwarth, D, 2006) |
| "In order to cure head and neck cancer without resection, chemotherapy (superselective intra-arterial infusion therapy with DCF) was conducted by anterograde, superselective intra-arterial infusion of 50-60 mg/m(2) of DOC and 50-60 mg/m(2) of CDDP via the femoral artery on day 1 followed by continuous intravenous instillation of 600-750 mg/m(2)/day of 5-FU for 5 days from day 2." | ( Furusaka, T, 2006) |
| "Treatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare." | ( Aliff, T; Fleisher, M; Fury, MG; Gerald, W; Hann, L; Lis, E; Pfister, DG; Venkatraman, E; Wong, R; Zahalsky, A, 2007) |
| "Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival." | ( Grierson, JR; Krohn, KA; Ng, P; O'Sullivan, J; Peterson, LM; Rajendran, JG; Scharnhorst, J; Schwartz, DL, 2006) |
| "Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004." | ( Grierson, JR; Krohn, KA; Ng, P; O'Sullivan, J; Peterson, LM; Rajendran, JG; Scharnhorst, J; Schwartz, DL, 2006) |
| "Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine." | ( Aekmahachai, M; Chiewvit, S; Chitapanarux, I; Khorprasert, C; Kongthanarat, Y; Lorvidhaya, V; Panichevaluk, A; Phromratanapongse, P; Pusuwan, P; Ratchadara, S; Saengsuda, Y; Shotelersuk, K; Sirilipoche, S; Sukthomya, V; Suntornpong, N; Swangsilpa, T; Tesavibul, C; Veerasarn, V, 2006) |
| "Head and neck cancers are commonly treated with the DNA-damaging agent cisplatin." | ( Burkitt, K; Ljungman, M, 2007) |
| "Twenty-five patients with head and neck cancer at various sites were planned for radiation therapy using positron emission tomography/computed tomography (PET/CT)." | ( Ashamalla, H; Bieniek, E; Evola, A; Goswami, G; Guirgius, A; Mokhtar, B; Oldroyd, R; Parikh, K; Rafla, S, 2007) |
| "Patients with head and neck cancer receive high doses of localized irradiation therapy, which results in destruction of salivary gland secretion ability." | ( Aframian, DJ; Davidovich, E; Peretz, B, 2007) |
| "Nude mice with UMSCC-1 head and neck cancer xenografts received either single, double, or triple agent therapy with an EGFR inhibitor (either cetuximab or gefitinib), gemcitabine, and/or radiation for 3 weeks." | ( Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S, 2007) |
| "We studied 375 patients with head and neck cancer who had been hospitalized from January 1998 to October 2005, to evaluate and treat the disease." | ( Horiuchi, C; Kawakami, M; Kondo, N; Matsuda, H; Mikami, Y; Nagao, J; Nishimura, G; Satake, K; Taguchi, T; Tsukuda, M; Yoshida, T, 2007) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| "As primary treatment for head and neck cancer moves toward radiation therapy, microsurgical reconstruction is playing an increasing role for those patients developing radiation-related complications." | ( Davison, SP; Sandel, HD, 2007) |
| "Head and neck cancer patients are treated with various therapeutic regimens, including chemotherapy with 5-FU at a dose of 600 mg m(-2) day(-1) with radiotherapy." | ( Beneton, M; Blasco, H; Boisdron-Celle, M; Calais, G; Chapet, S; Denis, F; Deporte-Fety, R; Giraudeau, B; Le Guellec, C; Narcisso, B, 2007) |
| "We conducted a prospective study of 540 head and neck cancer patients treated by radiation therapy." | ( Bairati, I; Fortin, A; Gélinas, M; Jobin, E; Meyer, F; Nabid, A; Têtu, B, 2007) |
| "We collected 92 biopsies from untreated head and neck cancer patients subsequently given cisplatin-based chemoradiation (RADPLAT) for advanced squamous cell carcinomas (HNSCC)." | ( Atsma, D; Begg, AC; Hoebers, FJ; Hofland, I; Nuyten, DS; Pimentel, N; Pramana, J; Rasch, CR; Van den Brekel, MW; van Velthuysen, ML; Wessels, LF, 2007) |
| "Patients with head and neck cancer undergoing radiation treatment develop painful mouth sores described as mucositis." | ( Anderson, K; Ghalie, R; Homel, P; Loewen, G; Mori, M; Portenoy, R; Shaiova, L, 2007) |
| "Two hundred eighty-two patients with head and neck cancer received a 14-day treatment of either single-dose MBT or MOG administered in 4 divided doses." | ( Allavena, C; Attali, P; Bastit, L; Bensadoun, RJ; Calais, G; Céruse, P; Daoud, J; El Gueddari, B; Gourmet, R; Rosikon, A, 2008) |
| "Untreated head and neck cancer patients frequently have nutritional status parameters indicating heightened risk for malnutrition-related complications but inadequate masticatory function is not a causative factor." | ( Friedlander, AH; Kawakami, KT; Tajima, T; Tomlinson, J; Wang, MB, 2008) |
| "Blood samples from 16 head and neck cancer patients were obtained at different times, just before treatment, at the 1st and 22nd sessions, at the end of radiotherapy, and one, four and 12 months later." | ( Barquinero, JF; Barrios, L; Caballín, MR; Craven-Bartle, J; de Vega, JM; Ribas, M; Xunclà, M, 2008) |
| "Seven patients with head and neck cancers were imaged twice with FMISO PET, separated by 3 days, before radiotherapy." | ( Humm, J; Lee, N; Lin, Z; Ling, CC; Mechalakos, J; Nehmeh, S; Schoder, H, 2008) |
| "Administration of [(18)F]EF3 in head and neck cancer patients is feasible and safe." | ( Christian, N; De Bast, M; Geets, X; Gillart, J; Grégoire, V; Labar, D; Lee, J; Levêque, P; Lonneux, M; Mahy, P, 2008) |
| "Cisplatin has been widely used to treat head and neck cancer." | ( Burkitt, K; Ljungman, M, 2008) |
| "Twenty patients diagnosed with head and neck cancer were treated with intensity modulated radiation therapy with an intention to spare the salivary gland function." | ( Collan, J; Heikkonen, J; Joensuu, H; Kairemo, K; Kangasmäki, A; Kouri, M; Mäkitie, A; Saarilahti, K; Tenhunen, M, 2008) |
| "As therapy for locoregionally advanced head and neck cancer (HNC) has evolved, treatment has become increasingly aggressive and cure rates have risen." | ( Posner, M; Vermorken, JB, 2008) |
| "In patients with advanced squamous cell head and neck cancer, the haemoglobin level prior to induction chemotherapy is significantly related to outcome including response and survival." | ( Baghi, M; Gstoettner, W; Hambek, M; Knecht, R; Moertel, S; Strebhardt, K; Wagenblast, J, 2008) |
| "Head and neck cancers are treated by a combination of surgery, radiotherapy and/or chemotherapy." | ( Eckstein, N; Gosepath, EM; Györffy, B; Hamacher, A; Kassack, MU; Lage, H; Royer, HD; Servan, K; von Jonquieres, G, 2008) |
| "A total of 62 head-and-neck cancer patients treated with curative intent were included in this prospective study." | ( Bentz, BG; Hitchcock, YJ; Shrieve, DC; Szabo, A; Tward, JD, 2009) |
| "Hypoxia in patients with head-and-neck cancer (HNC) is well established and known to cause radiation resistance and treatment failure in the management of HNC." | ( Castellano, I; Charles-Edwards, E; Clarke, P; Fisher, C; Harrington, K; Leach, M; Mears, D; Newbold, K; Nutting, C; Rhys-Evans, P; Sohaib, A, 2009) |
| "Therefore, we evaluated QOL in head and neck cancer patients during palliative chemotherapy with cisplatin and docetaxel." | ( Guntinas-Lichius, O; Klussmann, JP; Rühlow, S; Veelken, F, 2009) |
| "Although head and neck cancer is not one of the most common cancers, it is a debilitating disease with poor prognosis and considerable post-treatment normal tissue toxicity." | ( Marcu, LG, 2009) |
| "Recurrent/metastatic head and neck cancer remains a devastating disease with insufficient treatment options." | ( Christensen, JG; Cohen, EE; El Dinali, M; Faoro, L; Jagadeeswaran, R; Janamanchi, V; Kanteti, R; Klein-Szanto, A; Krishnaswamy, S; Lingen, MW; Martin, L; Nallasura, V; Salgia, R; Seiwert, TY; Vokes, EE; Yala, S, 2009) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy from December 1998 to March 2006 were reviewed retrospectively." | ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2009) |
| "A total of 8 patients with head and neck cancer underwent (18)F-FLT PET scans (7 patients at baseline and after 5 d [10 Gy] of radiation therapy given with concomitant chemotherapy and 1 patient only at baseline)." | ( Boles Ponto, LL; Buatti, JM; Dornfeld, KJ; Graham, MM; Menda, Y; Schultz, MK; Sunderland, JJ; Tewson, TJ; Watkins, GL, 2009) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "The study included 45 head and neck cancer patients who underwent FDG-PET scanning before radiotherapy." | ( Aoyama, H; Homma, A; Nishioka, T; Onimaru, R; Shirato, H; Suzuki, K; Tamaki, N; Tsuchiya, K; Yasuda, M, 2009) |
| "The main aim of the research on head and neck cancer probably lies in the identification of biomolecular markers that are able to predict clinical behaviour, thus allowing appropriate treatment tailoring." | ( Caponigro, F; Ionna, F; Longo, F; Perri, F, 2009) |
| "Treatment of head and neck cancers is still rather poor and worldwide new treatment options are sought." | ( Baatenburg de Jong, RJ; Noteborn, MH; Schoop, RA; Verdegaal, EM, 2010) |
| "Patients with locally advanced head and neck cancer, and who had not previously undergone surgery, were randomly assigned to one of four groups in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233); radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy (SIM alone; n=166); or 14 and 28 days after completing radiotherapy (SUB alone, n=160); or both (SIM+SUB; n=154)." | ( Glaholm, J; Gupta, N; Hackshaw, A; Hutchison, I; Kadalayil, L; Macdougall, H; Monson, K; Tobias, JS, 2010) |
| "Nine patients with head-and-neck cancer underwent computerized tomography (CT) simulation and [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) to compare the radiotherapy target volumes." | ( Barret, O; de Clermont-Gallerande, H; De-Mones-Del-Pujol, E; Demeaux, H; Fernandez, P; Henriques de Figueiredo, B; Kantor, G; Lagarde, P; Richaud, P, 2009) |
| "Thirteen newly diagnosed head-and-neck cancer patients with metastatic neck nodes underwent DCE-MRI and (18)F-FMISO PET imaging before chemotherapy and radiotherapy." | ( Fury, MG; Humm, JL; Jansen, JF; Koutcher, JA; Lee, NY; Pfister, DG; Schöder, H; Shukla-Dave, A; Stambuk, HE; Wang, Y, 2010) |
| "HPV/p16-positive head and neck cancers (HNSCC) show superior response to radiotherapy, compared with virus-negative tumours." | ( Alsner, J; Eriksen, JG; Hamilton-Dutoit, S; Lassen, P; Overgaard, J; Tramm, T, 2010) |
| "Patients with head and neck cancer submitted to the conventional radiotherapy treatment, combined with the chemotherapy with cisplatin, presented a high incidence of decreased hearing by the end of treatment." | ( Arruda, GV; Dell'Aringa, AH; Dell'aringa, AR; Esteves, MC; Isaac, ML; Júnior, JL; Rodrigues, AF, 2009) |
| "Evaluation of treatment of head and neck cancer." | ( Horiuchi, C; Komatsu, M; Matsuda, H; Nishimura, G; Taguchi, T; Takahashi, M; Tsukuda, M; Watanabe, M, 2009) |
| "Chemoradiation for head and neck cancer may produce severe glucose metabolism alteration during treatment." | ( Borok, TL; Dutta, S; Jo, BH; Karlsson, U; Lee, H; Martinez, T; Nguyen, LM; Nguyen, N; Nguyen, NP; Sallah, S; Vinh-Hung, V; Vos, P, 2009) |
| "Advanced head and neck cancers are one of the most challenging cancers facing the oncologists due to their aggressiveness attributable to the high hypoxic content and the tumour's ability to repopulate during radiotherapy." | ( Bezak, E; Marcu, L, 2010) |
| "Clinical application of FDG-PET in head and neck cancer includes identification of metastases, unknown primary head and neck malignancy, or second primary carcinoma, and also recurrent tumor after treatment." | ( Arisaka, Y; Endo, K; Hanaoka, H; Higuchi, T; Ishikita, T; Miyakubo, M; Miyashita, G; Nakasone, Y; Negishi, A; Oriuchi, N; Paudyal, B; Paudyal, P; Yokoo, S, 2010) |
| "The management of head and neck cancer requires skilled integration of multiple modalities such as surgery, radiation, chemotherapy and hyperthermia." | ( Dixit, R; Gupta, S; Huilgol, NG, 2010) |
| "In patients with advanced head and neck cancer who have received combined therapy, a second post-treatment PET/CT examination to check for late recurrences should be performed within 4-6 months after the first post-treatment PET/CT examination." | ( Ito, K; Kubota, K; Matsuda, H; Morooka, M; Shiibashi, M; Yokoyama, J, 2010) |
| "Patients receiving C-IMRT for head-and-neck cancer had repeat CT scans at weeks 2, 3, 4, and 5 during radiotherapy." | ( Barbachano, Y; Bhide, SA; Burke, K; Davies, M; El-Hariry, IA; Hansen, V; Harrington, KJ; McNair, HA; Newbold, K; Nutting, CM, 2010) |
| "Two different head and neck cancer cell lines (HEp-2 and Ca9-22) were treated with docetaxel at IC(10) and IC(50) concentrations." | ( Kimura, T; Kogashiwa, Y; Kohno, N; Sakurai, H, 2010) |
| "Forty-three patients with head and neck cancer were treated with helical tomotherapy." | ( Ceulemans, G; Everaert, H; Farrag, A; Storme, G; Voordeckers, M, 2010) |
| "Fourteen subjects with head and neck cancer underwent FLT positron emission tomography (PET) at baseline and after 10 Gy of radiation therapy." | ( Anderson, C; Buatti, JM; Dornfeld, KJ; Graham, MM; Gupta, AK; McGuire, S; Menda, Y; Ponto, LL; Schultz, MK; Sunderland, JJ; Tewson, TJ; Watkins, GL, 2010) |
| "A total of 32 patients with head and neck cancers who had both pretherapy and posttherapy FDG PET-CT scans were retrospectively analyzed." | ( Franceschi, D; Kaloudis, E; Matthews, R; Relan, N; Shrestha, P, 2010) |
| "Occasionally, head and neck cancer patients treated with high-energy X-rays and gamma rays have titanium dental implants." | ( Friedrich, RE; Krüll, A; Todorovic, M; Todrovic, M, 2010) |
| "Forty-seven patients with head-and-neck cancer who received pretreatment and posttreatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study." | ( Chu, K; Fischbein, NJ; Graves, EE; La, TH; Le, QT; Loo, BW; Maxim, PG; Murphy, JD; Quon, A, 2011) |
| "This study included 82 patients with head and neck cancer undergoing radiotherapy and referred to the Pain and Rehabilitation Centre at Linkoping University Hospital in Sweden because of OM-induced pain." | ( Larsson, B; Ling, IS, 2011) |
| "We report that cisplatin treatment of head and neck cancer cells results in a transient accumulation of cisplatin-resistant, small, and IL-6-positive cells that are highly tumorigenic." | ( Guminski, AD; Jabbar, IA; Leo, PJ; Poth, KJ; Saunders, NA; Thomas, GP, 2010) |
| "Head and neck cancer is treated mainly with surgery and radiotherapy." | ( Henríquez-Hernández, LA; Lara, PC; Lloret, M; Pinar, B; Rodríguez-Gallego, C; Saavedra, MM, 2010) |
| "Included were 78 patients with head and neck cancer who were undergoing radiotherapy." | ( Clark, LJ; Montgomery, J; Rana, I; Singh, J; Syed, MI, 2010) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy between December 1998 and March 2006 were reviewed retrospectively." | ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2010) |
| "Nude rats bearing human head and neck cancer and non-small cell lung cancer (NSCLC) xenografts were treated with intetumumab and fractionated local tumor radiotherapy." | ( Knox, SJ; Marshall, DJ; Ning, S; Tian, J, 2010) |
| "Head and neck cancer cells were treated with guggulsterone (GS)." | ( Chauhan, S; Macha, MA; Matta, A; Ralhan, R; Siu, KM, 2010) |
| "Using in vitro models of head and neck cancer, we showed 14-3-3 zeta as a key player regulating apoptosis in GS treated SCC4 cells." | ( Chauhan, S; Macha, MA; Matta, A; Ralhan, R; Siu, KM, 2010) |
| "For head-and-neck cancer and prostate cancer, the fraction of tumor clonogens killed over a full treatment course decreases by up to a factor of ∼10(3) as the dose per fraction is increased from 2 to 24 Gy and from 2 to 18 Gy, respectively." | ( Brown, JM; Carlson, DJ; Chen, ZJ; Keall, PJ; Loo, BW, 2011) |
| "Head-and-neck cancer patients who underwent FDG-PET before a course of curative intent radiotherapy were retrospectively analyzed." | ( Brizel, DM; Chino, J; Higgins, KA; Hoang, JK; Roach, MC; Turkington, TG; Yoo, DS, 2012) |
| "Although radiotherapy is effective for head and neck cancer patients, the local pain evoked by the irradiation itself reduces food intake and frequently halts the treatment." | ( Nakagawa, T; Nomoto, S; Sakata, T; Sueta, T; Takase, H; Yamano, T, 2011) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "The change in SUV observed in head and neck cancer patients treated with chemoradiation shows the potential for using [(18)F]FLT PET images for identifying active bone marrow and monitoring changes due to radiation dose." | ( Bayouth, JE; Boles Ponto, LL; Buatti, J; Gross, B; McGuire, SM; Menda, Y, 2011) |
| "Patients treated for squamous cell head and neck cancer (SCCHN) in 2006-2007 were evaluated as to necessity/number of replannings, weight loss, dose, and plan parameters." | ( Bendl, R; Debus, J; Huber, PE; Jensen, AD; Münter, MW; Nill, S, 2012) |
| "In head and neck cancer (HNC) various treatment strategies have been developed to improve outcome, but selecting patients for these intensified treatments remains difficult." | ( Kaanders, JH; Oyen, WJ; Schinagl, DA; Span, PN, 2011) |
| "Radiochemotherapy of head and neck cancer causes severe mucositis in most patients." | ( Alfonsi, M; Bardet, E; Berger, D; Cerezo, L; Chen, MG; Emmerson, L; Foa, P; Giralt, J; Henke, M; Lizambri, R; Salzwimmer, M, 2011) |
| "Patients with locally advanced head and neck cancer were treated with concurrent chemoradiotherapy using three courses of cisplatin." | ( Ando, A; Fujimoto, Y; Hiramatsu, M; Hirasawa, N; Ishihara, S; Ishizuka, M; Itoh, Y; Kitagawa, K; Miyagawa, Y; Nakashima, T; Sano, M; Yamada, K, 2011) |
| "Celebrex and radiotherapy in advanced head and neck cancer." | ( Cvek, J; Dusek, L; Feltl, D; Halamka, M; Horacek, J; Kominek, P; Kubes, J; Zavadova, E, 2011) |
| "Head and neck cancer exhibits hypoxia, inducing aggressive biologic traits that impart resistance to treatment." | ( Hendrickson, K; Krohn, K; Peterson, L; Phillips, M; Rajendran, J; Smith, W, 2011) |
| "The majority of patients with head and neck cancer are treated with concurrent chemoradiotherapy." | ( Altundag, O; Besen, A; Disel, U; Karadeniz, C; Kose, F; Ozyilkan, O; Sezer, A; Sumbul, T, 2011) |
| "In patients with head and neck cancer, concurrent chemoradiotherapy with weekly cisplatin might be as effective as concurrent chemoradiotherapy with bolus cisplatin." | ( Altundag, O; Besen, A; Disel, U; Karadeniz, C; Kose, F; Ozyilkan, O; Sezer, A; Sumbul, T, 2011) |
| "Patients with stage III-IVB head and neck cancer received cisplatin, docetaxel, and cetuximab (TPE) followed by radiotherapy, cisplatin, and cetuximab (XPE) and maintenance cetuximab in a phase II clinical trial." | ( Argiris, A; Branstetter, BF; Feinstein, T; Ferris, RL; Gooding, W; Grandis, JR; Lee, SC; Seethala, R; Thomas, S; Wang, L, 2011) |
| "Head and neck cancer patients received initial targeted therapy (TT) treatment with erlotinib and/or bevacizumab, followed by radiotherapy and concurrent cisplatin with synchronous TT." | ( Barboriak, DP; Brizel, DM; Carroll, MD; Cleland, E; Craciunescu, OI; MacFall, JR; Muradyan, N; Yoo, DS, 2012) |
| "Chemoradiotherapy for head and neck cancer is associated with a high incidence of severe oral mucositis; an adverse, painful event." | ( Hushimi, C; Inoue, T; Kamata, S; Kobayashi, M; Masubuchi, T; Miura, K; Moya, M; Tada, Y; Tajima, H; Tosaka, C, 2011) |
| "Head and neck cancer patients who were to receive definitive or postoperative chemoradiotherapy were enrolled." | ( Akimoto, T; Asai, M; Homma, A; Iwae, S; Kato, K; Kirita, T; Matsuura, K; Monden, N; Ota, Y; Otsuru, H; Tachibana, H; Tahara, M; Zenda, S, 2011) |
| "Smoking outcomes among lung and head and neck cancer patients appear to have remained the same over the last two decades despite the availability of an increased number of pharmacotherapy options to treat tobacco dependence." | ( Bueno, R; Catalano, P; Cooley, ME; Emmons, KM; Haddad, RI; Johnson, BE; Wang, Q, 2012) |
| "Data confirm that head and neck cancer patients misrepresent true tobacco use during treatment." | ( Arnold, SM; Cummings, KM; Gal, TJ; Hyland, AJ; Kudrimoti, MR; Marshall, JR; Rangnekar, VM; Singh, AK; Valentino, JP; Warren, GW, 2012) |
| "Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal whole saliva production ≥0." | ( Berk, L; Cardinale, F; James, JL; Lukaszczyk, B; Nguyen-Tân, PF; Sagar, S; Singh, AK; Wong, RK; Wyatt, G; Yeh, AM, 2012) |
| "Carbon ion radiotherapy for head and neck cancer showed the therapeutic effectiveness for malignant melanoma and adenoid cystic carcinoma without severe morbidity of the normal tissues." | ( Bessyo, H; Hasegawa, A; Jingu, K; Kamada, T; Mizoe, JE; Morikawa, T; Okamoto, Y; Takagi, R; Tonoki, M; Tsuji, H; Tsujii, H, 2012) |
| "Surgical treatment of head and neck cancer frequently results in defects that challenge conventional prosthetic rehabilitation." | ( Dholam, KP; Gurav, SV, 2012) |
| "Patients with stages III to IV head and neck cancer were randomized to receive radiotherapy with cisplatin (CIS) or CIS plus TPZ (TPZ/CIS)." | ( Cao, H; Fisher, R; Giaccia, A; Graves, E; Hicks, RJ; Kong, C; Le, QT; McArthur, GA; O'Sullivan, B; Oliner, KS; Peters, L; Rischin, D; Young, RJ, 2012) |
| "ALDH1 activity of head and neck cancer cells with quercetin treatment was assessed by the Aldefluor assay flow cytometry analysis." | ( Chang, WW; Chang, YC; Feng, HP; Hu, FW; Lan, C; Tsai, LL; Wang, HH; Yu, CC, 2013) |
| "The migration ability of head and neck cancer-derived sphere cells was lessened under quercetin treatment partially due to the decreased productions of Twist, N-cadherin, and vimentin." | ( Chang, WW; Chang, YC; Feng, HP; Hu, FW; Lan, C; Tsai, LL; Wang, HH; Yu, CC, 2013) |
| "Twenty patients (10 with head and neck cancer and 10 with non-small cell lung cancer) underwent (18)F-FDG PET/CT for radiotherapy planning, and 20 patients (10 with head and neck cancer and 10 with non-small cell lung cancer) underwent (18)F-FDG PET/CT for staging." | ( Lin, M; Lin, P; Sam, S; Shon, IH; Vinod, SK, 2012) |
| "Patients with locoregionally advanced head and neck cancer treated with concomitant boost accelerated radiation plus chemotherapy show significant risks of mortality from causes other than disease progression." | ( Gómez-Millán, J; Lupiañez, Y; Medina, JA; Rueda, A; Sachetti, A; Toledo, MD; Trigo, JM, 2013) |
| "Twenty-five patients with stage III/IV head and neck cancer were investigated with [(18)F]-fluoromisonidazole (FMISO) PET/CT at four time points during radiochemotherapy (baseline, 8-10 Gy, 18-20 Gy,50-60 Gy)." | ( Abolmaali, N; Abramyuk, A; Appold, S; Baumann, M; Haase, R; Kotzerke, J; Perrin, R; Steinbach, J; Zips, D; Zöphel, K, 2012) |
| "Radiotherapy when used in head and neck cancer treatment can produce side effects in patients such as the trismus." | ( Alvi, HA; Rashmikant, US; Singh, K; Singh, RK, 2012) |
| "Treatment of head and neck cancer with radiation often results in damage to surrounding normal tissues such as salivary glands." | ( Arnett, DG; Burd, R; Hill, GA; Klein, RR; Limesand, KH; Martin, KL, 2012) |
| "Consequently, the majority of head and neck cancer patients are at risk of developing osteoradionecrosis of the jaws, which is the most serious and important complication of radiotherapy." | ( Cheriex, KC; Mureau, MA; Nijhuis, TH, 2013) |
| "Eleven patients with untreated head and neck cancer underwent 2 (18)F-FMISO PET/CT scans ((18)F-FMISO(1) and (18)F-FMISO(2)) with a 48-h interval prospectively." | ( Ito, YM; Kasai, K; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Shirato, H; Tamaki, N; Yasuda, K, 2013) |
| "Human papillomavirus (HPV)-related head and neck cancer has been associated with an improved prognosis in patients treated with radiotherapy (RT) +/- chemotherapy (CT); however, RT combined with epidermal growth factor receptor (EGFR) inhibitors has not been fully studied in this group of patients." | ( Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM, 2013) |
| "Forty-eight patients with head and neck cancer underwent (18)F-FLT PET/CT before and during the second and fourth weeks of radiotherapy or chemoradiotherapy." | ( Bussink, J; Hoeben, BA; Kaanders, JH; Oyen, WJ; Span, PN; Troost, EG; van Herpen, CM, 2013) |
| "In head and neck cancer, a change in (18)F-FLT uptake early during radiotherapy or chemoradiotherapy is a strong indicator for long-term outcome." | ( Bussink, J; Hoeben, BA; Kaanders, JH; Oyen, WJ; Span, PN; Troost, EG; van Herpen, CM, 2013) |
| "Early detection and treatment of head and neck cancer has led to increased patient survival." | ( Hussain, T; Kotnis, A; Mulherkar, R; Sarin, R, 2013) |
| "The combined treatment inhibited head and neck cancer cell growth significantly more potently than either single agent alone in cell line and xenograft models, and resulted in greater inhibition of cell-cycle progression at G1 phase than either single drug." | ( Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H, 2013) |
| "Radiotherapy as part of head and neck cancer treatment leaves patients requiring much dental rehabilitation in a compromised environment that is difficult for the patient and the dental team to manage." | ( Al-Khayatt, A; Briggs, P; Eliyas, S; Porter, RW, 2013) |
| "Its utility in the initial staging of head and neck cancer is becoming widely accepted, however, its role in the post-therapy management of the neck following chemoradiotherapy in node-positive head and neck cancer remains unresolved." | ( Adams, G; Gundelach, R; Porceddu, SV; Pryor, DI, 2013) |
| "We studied head and neck cancer patients (n=23) on 5-FU and cisplatin combination therapy attending a tertiary care cancer research institute in Gujarat, India, to understand the effect of a particular genotype on toxicity." | ( Dhawan, D; Padh, H; Panchal, H; Shukla, S, 2013) |
| "IMRT and helical tomotherapy for head and neck cancer (HNC) treatment are associated with higher doses to certain non-target tissues than traditional static beam techniques." | ( Cleary, KP; Geye, HM; Harari, PM; Kozak, KR; Kruser, TJ; Rice, SR; Tome, WA, 2013) |
| "Head and neck cancer patients treated with a platinum-based regimen were included in the analysis." | ( Cho, H; Inohara, H; Nakahara, S; Takenaka, Y; Yamamoto, M; Yamamoto, Y, 2013) |
| "Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis." | ( Carpentier, I; Deschutter, H; Menten, J; Nuyts, S; Van Beek, K, 2013) |
| "Human head and neck cancer cells AMC-HN3 were treated with cisplatin- and ALA-mediated PDT individually, and also in combination." | ( Ahn, JC; Biswas, R; Chung, PS; Lee, YK; Mondal, A, 2014) |
| "Patients with head and neck cancer experience significant weight loss secondary to concurrent chemoradiotherapy (CCRT)." | ( Alexander, N; Feng, F; Fig, L; Jackson, W; Jolly, S; Schipper, M, 2014) |
| "Patients with head and neck cancer (HNC) are at high risk for oropharyngeal dysphagia (OD) following surgical therapy." | ( Eberle, S; Hey, C; Lange, BP; Sader, R; Stöver, T; Wagenblast, J; Zaretsky, Y, 2013) |
| "In the present study, human head and neck cancer cells were treated with radachlorin mediated photodynamic therapy and the chemotherapy drug, carboplatin singly or in combination." | ( Ahn, JC; Biswas, R; Chung, PS; Hwang, H, 2013) |
| "Head-and-neck cancer patients tolerated everolimus at therapeutic doses (5 mg/day) given with weekly cisplatin and intensity modulated radiation therapy." | ( Fury, MG; Ganly, I; Haque, S; Heguy, A; Ho, AL; Katabi, N; Korte, S; Lee, NY; Lisa, D; Patel, S; Pfister, DG; Rao, S; Shah, J; Shaha, A; Shen, R; Sherman, E; Wong, RJ, 2013) |
| "Head and neck cancer (H&NCa) patients have an increased risk of malnutrition and dysphagia because of their malignancy and the adverse events of therapy." | ( Dekovich, AA; Lamberth, JR; Nevah, MI, 2014) |
| "Gargling with turmeric by head and neck cancer patients undergoing radiation therapy provided significant benefit by delaying and reducing the severity of mucositis." | ( Baliga, MS; Dinkar, C; Fayad, R; Rai, MP; Rao, P; Rao, S; Vaishnav, LK, 2014) |
| "Radiotherapy of head and neck cancer induces changes in tumour cell proliferation during treatment, which can be depicted by the PET tracer (18)F-fluorothymidine (FLT)." | ( Arens, AI; Bussink, J; Grégoire, V; Grootjans, W; Hatt, M; Hoeben, BA; Kaanders, JH; Lee, JA; Oyen, WJ; Troost, EG; Visser, EP; Visvikis, D, 2014) |
| "In patients with head and neck cancer, FLAB proved to be the best performing method for segmentation of the PV on repeat FLT PET/CT scans during (chemo)radiotherapy." | ( Arens, AI; Bussink, J; Grégoire, V; Grootjans, W; Hatt, M; Hoeben, BA; Kaanders, JH; Lee, JA; Oyen, WJ; Troost, EG; Visser, EP; Visvikis, D, 2014) |
| "Advanced head and neck cancers are difficult to manage despite the large treatment arsenal currently available." | ( Marcu, LG, 2013) |
| "Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was monitored by repetitive PET imaging with the proliferation tracer 18F-FLT." | ( Bussink, J; Hoeben, BA; Kaanders, JH; Oyen, WJ; Troost, EG; van Herpen, CM, 2014) |
| "Five head and neck cancer patients, treated with radiotherapy and concomitant cetuximab following cetuximab induction, received four 18F-FLT PET-CT scans before and during treatment." | ( Bussink, J; Hoeben, BA; Kaanders, JH; Oyen, WJ; Troost, EG; van Herpen, CM, 2014) |
| "Thirty-five patients with cancer of the head and neck underwent dynamic PET imaging as part of a study intended to evaluate the utility of quantitative, image-based metrics for assessment of early treatment response." | ( Armstrong, J; Borel, S; Caldwell, C; Kusano, M; Poon, I; Sattarivand, M, 2014) |
| "A total of 114 patients with head and neck cancer whose radiotherapy fields included the thyroid gland were analysed." | ( Kim, MY; Wu, HG; Yu, T, 2014) |
| "A total of 50 patients with head and neck cancer requiring >60 Gy of curative radiotherapy/chemoradiotherapy were enrolled in the study." | ( Azmidah, A; Baliga, MS; D'souza, PF; Fayad, R; Haniadka, R; Jayachander, D; Jimmy, R; Palatty, PL; Rai, MP; Rao, S; Ravi, R; Simon, P; Thilakchand, KR, 2014) |
| "Criteria were tested on head and neck cancer patients treated with (chemo-)radiotherapy ([C]RT) and compared with the Common Terminology Criteria for Adverse Events version 4 (CTCAEv4) and the American Speech-Language-Hearing Association criteria (ASHA)." | ( Balm, AJ; de Boer, JP; Dreschler, WA; Latenstein, MN; Rasch, CR; Theunissen, EA; van der Baan, S; Zuur, CL, 2014) |
| "In head and neck cancers, tumour cell repopulation during chemotherapy is one reason for treatment failure." | ( Marcu, LG, 2014) |
| "Patients treated for head and neck cancer frequently develop dysphagia." | ( Logemann, J; Mittal, BB; Pierce, M; Rogus-Pulia, NM; Zecker, SG, 2015) |
| "Improved survival for patients with head and neck cancers (HNC) with recurrent and metastatic disease warrants that cancer therapy is specific, with protected delivery of the therapeutic agent to primary and metastatic cancer cells." | ( Ahmed, K; Kimbrough, TG; Korman, VL; Kren, BT; Ondrey, FG; Trembley, JH; Unger, GM; Vogel, RI, 2014) |
| "Standard therapy for advanced head and neck cancer consists of a combination of surgery and radiation." | ( Bhat, M; Hegde, S; Lasrado, S; Luis, NA; Moras, K; Pinto, GJ; Sathian, B, 2014) |
| "Head and neck cancer without distant metastases is amenable to various modalities of treatment." | ( Bhatt, HC; Pandey, KC; Pant, NK; Revannasiddaiah, S, 2014) |
| "Current treatment strategies for head and neck cancer are associated with significant morbidity and up to 50% of patients relapse, highlighting the need for more specific and effective therapeutics." | ( Delia, D; El-Attar, R; Kulms, D; Lecis, D; Odell, E; Papenfuss, K; Raulf, N; Tavassoli, M; Walczak, H, 2014) |
| "Twenty-six eligible head and neck cancer patients who were to receive conventional radiation therapy at the radiation oncology department were randomised to receive an Aloe vera mouthwash or a benzydamine mouthwash." | ( Ashnagar, S; Bekhradi, R; Doroudgar, K; Hajimirzamohammad, M; Kazemian, A; Manifar, S; Mansourian, A; Mohammad, HM; Sahebjamee, M; Zadeh, MT, 2015) |
| "A consecutive series of 28 head and neck cancer patients submitted to radiotherapy (RT) was enrolled onto this mono-institutional single-arm prospective observational study." | ( Filippi, AR; Franco, P; Grosso, M; Lombardo, A; Moretto, F; Potenza, I; Rampino, M; Ricardi, U; Segantin, M; Taricco, D; Vallario, P, 2014) |
| "Eligible patients had head and neck cancers requiring palliative chemotherapy with ECOG PS 0-2 and adequate organ functions who could not afford cetuximab." | ( Arya, S; Banavali, S; Bhattacharjee, A; Bhosale, B; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Muddu, VK; Noronha, V; Patil, VM; Prabhash, K, 2015) |
| "A total of 11 patients with head and neck cancer who received concurrent chemoradiotherapy with S-1 were examined." | ( Futagami, K; Nakagawa, T; Nomoto, S; Ogata, K; Takase, H; Tokunaga, S; Yonekita, H; Yoshimitsu, K, 2014) |
| "Thirty-seven head and neck cancer patients who had undergone definitive radiotherapy and PET/CT at the Uludag University Medical Faculty Department of Radiation Oncology were investigated in order to determine the role of PET/CT in staging and radiotherapy planning." | ( Abakay, CD; Akpinar, T; Altay, A; Arslan, S; Ekinci, AS; Esbah, O; Kekilli, KE; Ozkan, L; Sen, F; Uslu, N, 2014) |
| "The outcome of MNNs in patients with head and neck cancer receiving chemoradiotherapy/radiotherapy can be predicted according to radiologic necrosis and N-TLG40% value." | ( Chen, SW; Hsieh, TC; Kao, CH; Lin, YC; Wang, YC; Yang, SN; Yen, KY, 2015) |
| "Head and neck cancer patients scheduled to undergo neoadjuvant cisplatin-based chemotherapy were eligible for enrollment." | ( Cheng, FC; Chien, LS; Jiang, RS; Lin, JC; Lin, YJ; Liu, SA, 2015) |
| "Patients diagnosed with breast or head and neck cancer who planned to received radiotherapy to neck as a definite or a part of their treatment enrolled in this prospective single-arm study from June 2012 to June 2013." | ( Aboelnaga, EM; Aboelnaga, MM, 2015) |
| "Current treatment for head and neck cancer includes chemotherapy with cisplatin, docetaxel and 5-fluorouracil (5-FU) and the response rates to these drugs in patients is 60-80%." | ( Das, D; Govindan, SV; Hicks, W; Kulsum, S; Kuriakose, MA; Pandian, RS; Seshadri, M; Suresh, A, 2015) |
| "Radiation-treated head and neck cancer (HNC) patients are at high risk for developing radiation vasculopathy, as evidenced by an increased stroke risk." | ( Ahn, P; deGoma, E; Hajj, J; Jacoby, D; Javaheri, A; Lin, A; Quon, H, 2015) |
| "Japanese patients with head and neck cancer who had received cisplatin-based chemotherapy were used as subjects." | ( Atsuda, K; Kagaya, H; Kondo, N; Ogawa, C; Saito, S; Suzuki, Y; Uesawa, Y; Yajima, A; Yatabe, M, 2015) |
| "Head and neck cancers have been widely studied concerning their sensitivity to radiation therapy." | ( Biau, J; Chautard, E; Lapeyre, M; Miroir, J, 2015) |
| "Patients with head and neck cancer or gynaecological cancer suffer from a number of primarily non-physical symptoms before starting combined chemo-radiotherapy." | ( Feyer, P; Hansen, O; Herrstedt, J; Iversen, TZ; Kristensen, G; Muhic, A; Okera, M; Ruhlmann, CH, 2015) |
| "This treatment strategy in head and neck cancer could mediate cisplatin chemoresistance by modulating therapeutic targets (STAT3 and Nrf2) and, at the same time, reduce cisplatin-related ototoxic adverse effects." | ( Eramo, SL; Fetoni, AR; Mezzogori, D; Paciello, F; Paludetti, G; Rolesi, R; Troiani, D, 2015) |
| "A cohort of 78 patients with advanced head and neck cancer treated with induction chemotherapy was assessed for clinical outcome and toxicity during treatment with curative intention." | ( Egle, A; Gaggl, A; Greil, R; Hufnagl, C; Hutarew, G; Magnes, T; Melchardt, T; Moser, G; Neureiter, D; Schlattau, A; Tränkenschuh, W; Weiss, L, 2015) |
| "Tumor hypoxia in head and neck cancers and other tumors in a clinical setting may also indicate resistance to radiation and/or chemotherapy." | ( Hirata, K; Tamaki, N, 2016) |
| "Twenty-nine patients with head and neck cancer underwent FAZA PET/CT before treatment." | ( Fujibayashi, Y; Harada, R; Inubushi, M; Koizumi, M; Obata, T; Saga, T; Tanimoto, K; Uno, T; Yoshikawa, K; Zhang, MR, 2016) |
| "Head and neck cancer patients treated with high-dose cisplatin and radiotherapy will suffer from hearing deficits." | ( Aarnisalo, A; Mäkitie, AA; Niemensivu, R; Saarilahti, K; Ylikoski, J, 2016) |
| "The rising incidence of head and neck cancer and the drawbacks of currently used therapeutic strategies such as salvage surgery followed by adjuvant chemo- or radiotherapy have encouraged pursuits for better therapeutic approaches." | ( Balasubramanian, G; Krishnan, UM; Mohan, A; Narayanan, S; Sethuraman, S, 2016) |
| "PET hypoxia imaging of head and neck cancer (HNC) has the potential to stratify the response to radiochemotherapy." | ( Chirla, R; Marcu, LG, 2016) |
| "We will recruit 48 individuals with head and neck cancer who will be starting their radiotherapy and randomize them to receive either gel of chamomile or cream of urea, as an intervention for prevention of radiation dermatitis." | ( Avelino, SR; Bontempo, Pde S; Ciol, MA; Dos Reis, PE; Dos Santos, MA; Ferreira, EB; Silva, LF; Vasques, CI; Vieira, NN, 2016) |
| "Although head and neck cancer (HNSCC) is the sixth most common tumor entity worldwide therapy options remain limited leading to 5-year survival rates of only 50 %." | ( Bootz, F; Brägelmann, J; Brossart, P; Deng, M; Duensing, S; Heasley, L; Kirfel, J; Kristiansen, G; Perner, S; Queisser, A; Sanders, C; Schröck, A; Thewes, B; Vogel, W; von Mässenhausen, A, 2016) |
| "Head and neck cancer (HNC) is characterized by epidermal growth factor receptor (EGFR) overexpression and radiotherapy (RT) resistance." | ( Astesana, V; Cavicchioli, F; Ghiglia, A; Gianello, L; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Russi, E; Tonissi, F; Vivenza, D, 2016) |
| "The accurate staging of head and neck cancer is vital to direct appropriate management strategies and to deliver the best radiation therapy and surgery." | ( Burkill, GJ; Connor, SE; Evans, RM; Raman, VV, 2016) |
| "Head and neck cancers (thyroid and head and neck squamous cell carcinoma (HNSCC)) are relatively common malignancies and although often curable at initial diagnosis, treatment of advanced disease is palliative in intent." | ( Spector, M; Swiecicki, PL; Worden, FP, 2016) |
| "For patients with head-and-neck cancer treated with definitive radiation, we have developed a prediction nomogram based on models that presented good discriminative ability in making predictions of tumour response to treatment." | ( Dias, J; Ferreira, B; Khouri, L; Lopes, MC; Rocha, H, 2016) |
| "A consecutive series of 50 head and neck cancer patients undergoing concomitant radio-chemotherapy with weekly cisplatin was analyzed." | ( Airoldi, M; Arcadipane, F; Cavallin, C; Fasolis, M; Franco, P; Garzino Demo, P; Martini, S; Ostellino, O; Pecorari, G; Rampino, M; Ricardi, U; Schena, M, 2017) |
| "Each year, 15,000 head and neck cancer are treated in France." | ( Ben Mrad, M; El Meddeb Hamrouni, A; Espenel, S; Garcia, MA; Guy, JB; Langrand-Escure, J; Magné, N; Rancoule, C; Trone, JC; Vallard, A; Xia, Y, 2017) |
| "Head and neck cancer patients treated with surgery often experience significant postoperative morbidities." | ( Leung, JS; Li, GK; Seto, A, 2017) |
| "In definitive radiation therapy for head and neck cancer, clinically uninvolved cervical lymph nodes are irradiated with a so-called 'elective dose' in order to achieve control of clinically occult metastases." | ( Dijkema, T; Doornaert, PA; Hoebers, FJ; Kaanders, JH; Kreike, B; Kunze-Busch, MC; Oyen, WJ; Raaijmakers, CP; Terhaard, CH; van den Bosch, S; Vergeer, MR; Wijers, OB, 2017) |
| "With increased survival of head and neck cancer patients because of improved therapy, the cardiovascular morbidity and mortality in them have become apparent and this is of clinical concern." | ( Bhatt, ML; Bisht, S; Goyal, M; Gupta, D; Shukla, P; Tiwari, S; Verma, NS, 2017) |
| "Patients with head and neck cancer undergoing concurrent CRT along with metformin treatment require more careful multidisciplinary assessment and supportive care to ensure successful completion of treatment and avoid treatment-related toxicities." | ( Chang, PH; Chen, EY; Chou, WC; Hsieh, JC; Wang, CH; Yang, SW; Yeh, KY, 2017) |
| "Eighteen head and neck cancer patients underwent time of flight PET/MRI before chemoradiotherapy." | ( Guo, QY; Han, CB; Ma, JT; Sun, HZ; Xin, J; Zhang, SM; Zheng, JH, 2017) |
| "For head and neck cancer therapy, co-delivery of two drugs, cisplatin (DDP) plus paclitaxel (PTX), are more effective than single drug therapy." | ( Dong, S; Ju, Z; Yang, J, 2016) |
| "Patients with head and neck cancer at a tertiary hospital in Australia referred for prophylactic gastrostomy prior to curative intent treatment were eligible for this single centre randomised controlled trial." | ( Banks, MD; Bauer, JD; Brown, TE; Hughes, BGM; Kenny, LM; Lin, CY, 2017) |
| "Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated." | ( Chan, K; Cheon, P; Chow, E; Chow, R; DeAngelis, C; Giotis, A; Lee, J; Pasetka, M; Stinson, J; Wan, BA, 2017) |
| "Thirty-nine head and neck cancer patients receiving concurrent chemoradiation (5 days/week of radiation plus chemotherapy three or six cycles)." | ( Hurst, C; Johns, J; Johns, NP; Khuayjarernpanishk, T; Onseng, K; Priprem, A; Subongkot, S, 2017) |
| "60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization." | ( Chaitanya, B; Chhaparwal, Y; Fernandes, D; Pai, KM; Yathiraj, PH, 2017) |
| "Treatment for head and neck cancers using definitive radiotherapy, with or without chemotherapy, is associated with significant acute toxicity." | ( Dixon, L; Garcez, K; Lee, LW; Slevin, N; Sykes, A; Thomson, D, 2017) |
| "Patients undergoing major surgery for head and neck cancer who were treated with the ERAS protocol and preoperative glucocorticoid administration had evidence of better hemodynamic stability and less inflammatory response than control patients." | ( Aoi, J; Asada, Y; Fujii, K; Goto, T; Imai, T; Kishimoto, K; Kurosawa, K; Matsumoto, K; Matsuura, K; Morita, S; Saijo, S; Satake, N; Yamaguchi, K, 2018) |
| "Twenty-nine head and neck cancer patients with metallic dental fillings who were scheduled to undergo fractionated external beam radiation therapy (RT) ± chemotherapy were enrolled." | ( Aggarwal, S; Chan, C; Hara, W; Le, QT; Say, C; Seol, SW; von Eyben, R; Wang, Z; Xing, L; Yang, Y, 2018) |
| "Head and neck cancer patients who had been treated with platinum-based chemotherapy from January 2014 to December 2015 were enrolled for review." | ( Huang, CY; Kang, BH; Lin, SC; Lin, YS; Liu, YH, 2018) |
| "In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies." | ( Fujii, M; Konishi, T; Nagamoto, H; Shibasaki, Y; Ueno, T; Yurikusa, T; Zenda, S, 2019) |
| "More than 80% head and neck cancer patients endured radiotherapy-induced xerostomia which impacts their quality of life (QoL)." | ( Chan, SY; Gong, JY; Han, LX; Ho, KL; Lim, RJ; Nik Nabil, WN; Shew, YS; Wong, YF; Xu, L, 2019) |
| "Thirty-eight patients with head-and-neck cancer underwent consecutive FDG and FMISO PET scans before any treatment." | ( Gafita, A; Hirata, K; Kroenke, M; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Tamaki, N; Watanabe, S, 2019) |
| "Herein, three elderly men with advanced head and neck neoplasms were treated with apatinib and S-1." | ( Han, X; Huang, G; Li, W; Meng, M; Ni, Y; Wang, J; Wei, Z; Yang, X; Ye, X, 2019) |
| "Twelve patients with head and neck cancer scheduled for surgery received systemic administration of a tumor-specific contrast-agent (panitumumab-IRDye800CW)." | ( Birkeland, A; Colevas, AD; Cunanan, K; Fakurnejad, S; Forouzanfar, T; Martin, B; Nishio, N; Rosenthal, E; S van den Berg, N; van Keulen, S, 2019) |
| "Induction chemotherapy (IC) for head and neck cancer (HNC) often causes severe side-effects." | ( Ikari, Y; Imanishi, Y; Ito, F; Mikoshiba, T; Nakahara, N; Ogawa, K; Ozawa, H; Saito, S; Sekimizu, M; Watanabe, Y, 2019) |
| "Head and neck cancer patients receiving 30-35 radiotherapy fractions with or without concurrent chemotherapy excluding those intolerant to xanthines, with any bleeding tendency were included." | ( El Wakeel, L; El-Hamamsy, M; Kelany, M; Saad, AS; Sayed, R, 2019) |
| "Medical records of 276 head/neck cancer patients were retrospectively assessed for persistent opioid use 1-year after curative-intent radiotherapy." | ( Abramowitz, MC; Elsayyad, N; Freedman, LM; Kwon, D; Masforroll, M; Rueda-Lara, MA; Samuels, MA; Samuels, SE; Sargi, ZB; Schumacher, LD; Zhao, W, 2020) |
| "Patients and method Fifty patients with head and neck cancer treated with radiotherapy (RT) or chemoradiation were included in the study." | ( Barczak, W; Kazmierska, J; Marciniak, M; Suchorska, W; Winiecki, T; Łuczewski, Ł, 2020) |
| "Head and neck cancers (HNSCC) are routinely treated with radiotherapy; however, normal tissue toxicity remains a concern." | ( Bridges, KA; Clump, DA; Faust, AZ; Ferris, RL; Frederick, MJ; Heffernan, TP; Mason, KA; Meyn, RE; Molkentine, DP; Molkentine, JM; Myers, JN; Pickering, CR; Sheth, A; Skinner, HD; Xie, T; Yang, L, 2021) |
| "Only studies on head-neck cancer reported moderate agreement probably explained by the lack of reproducibility of the patients positioning between pre- and post-treatment FDG-PET/CT; and by the rigid registration process of images limited by post-therapeutic changes that highly affect anatomical landmarks." | ( Abgral, R; Bourhis, D; Calais, J; Leclère, JC; Lucia, F; Salaün, PY; Schick, U; Vera, P, 2020) |
| "Many head and neck cancer patients who receive radiation therapy experience radiation-induced dysgeusia (RID), which has no standard treatment." | ( Aponte-Wesson, RA; Chambers, MS; Chi, WJ; Frank, SJ; Geng, Y; Li, Y; Myers, JN; Nogueras-González, GM; Otun, AO, 2020) |
| "Radiation for patients with head and neck cancer (HNC) is associated with painful mucositis that impacts the delivery of treatment and contributes to high symptom burden." | ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020) |
| "In order to enhance head and neck cancer (HNSCC) cells' sensitivity to the cytotoxic effects of CisPt combined treatments with RSV or CRM were used." | ( Bostan, M; Diaconu, CC; Hainarosie, R; Petrică-Matei, GG; Radu, N; Roman, V; Stefanescu, CD, 2020) |
| "There were 388 patients with head and neck cancer treated between January 2011 and December 2017 who met inclusion criteria." | ( Biedermann, GB; Bollig, CA; Clark, AD; Galloway, TLI; Gilley, DR; Jorgensen, JB; Kinealy, BP; Zitsch, RP, 2021) |
| "The high incidence of head and neck cancer in Central America and the Caribbean, together with limitations in the healthcare system for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) in this region necessitate a consensus of opinion based on a review of the literature on therapy with cisplatin plus radiation." | ( Alvarado-Muñoz, JF; Barillas, A; Cabreja, A; Falco, A; López, K; Morales, AR; Moreno, J; Nuñez, C; Prestol, R; Reynoso, G; Sánchez, NC, 2021) |
| "Cisplatin(CDDP)is a key drug for head and neck cancer therapy, but frequently induces severe adverse events including renal dysfunction." | ( Hoshi, A; Kobayashi, H; Kurihara, T; Momo, K; Sasaki, T; Shimane, T, 2021) |
| "Thirty-eight patients treated for head and neck cancer combined with radiotherapy(RTx)and tegafur- gimeracil-oteracil(S-1)between April 2012 and March 2015 were included." | ( Hoshi, A; Kobayashi, H; Kurihara, T; Momo, K; Sasaki, T; Shimane, T, 2021) |
| "Head and neck cancers (HNC) and their treatments cause dysfunction and distress." | ( Butow, PN; Dhillon, HM; Rutherford, C; Shunmugasundaram, C; Sundaresan, P, 2021) |
| "We identified a cohort of patients with head and neck cancer who received radiotherapy as part of curative treatment at our institution." | ( Abramowitz, MC; Elsayyad, N; Freedman, LM; Kwon, D; Masforroll, M; Rich, BJ; Rueda-Lara, MA; Samuels, MA; Samuels, SE; Sargi, ZB; Schumacher, LD; Zhao, W, 2021) |
| "Sixty chemotherapy naïve head and neck cancer patients completed the study." | ( El-Haggar, S; Ghonaim, E; Gohar, S, 2021) |
| "Postoperative pain after head and neck cancer surgery is commonly treated with opioids, which are associated with considerable side effects." | ( Chorath, K; Go, BC; Go, CC; Moreira, A; Rajasekaran, K, 2022) |
| "Patients with head and neck cancer (HNC) experience serious pain related to tumour, surgery, chemotherapy, and radiotherapy treatment (RT)." | ( Bäckryd, E; Peterson, A; Schaller, AKCS, 2021) |
| "Eighty patients with head and neck cancers and undergoing volumetric arc therapy were taken up for the study." | ( Choudhury, B; Das, N; Dixit, A; Goyal, A; Kaushal, D; Pareek, P; Patro, SK; Prakasan Nair, N; Soni, K, 2021) |
| "Head and neck cancer (HNC) has frequently an aggressive course for the development of resistance to standard chemotherapy." | ( Barillari, G; Bei, R; Benvenuto, M; Bonanno, E; Ciuffa, S; Coletta, M; Fazi, S; Focaccetti, C; Manzari, V; Masuelli, L; Modesti, A; Sbardella, D; Scimeca, M; Segni, M; Tundo, GR, 2021) |
| "We present a case of head and neck cancer under pain management with opioids, in which cancer pain was exacerbated after administration of nivolumab." | ( Itoh, H; Shiraiwa, K; Sumimoto, T; Tanaka, R; Tatsuta, R, 2022) |
| "A male patient with head and neck cancer was hospitalized for the second-line treatment of nivolumab." | ( Itoh, H; Shiraiwa, K; Sumimoto, T; Tanaka, R; Tatsuta, R, 2022) |
| "The medical records of patients with head and neck cancer who received radiation therapy from January 2012 to July 2016 were reviewed." | ( Chen, AM; Ganju, R; Lominska, C; Morse, R; Neeranjun, R; TenNapel, M, 2022) |
| "sixty head and neck cancer patients who have been scheduled to undergo radiotherapy were randomly assigned to receive radiotherapy plus licorice mucoadhesive film (30) or radiotherapy plus placebo mucoadhesive film." | ( Isfahani, MN; Karimi, F; Pakravan, F; Salehabad, NH, 2021) |
| "One hundred twenty patients with head and neck cancer undergoing radiotherapy participated in the study and were randomly assigned into three treatment groups using block randomization method." | ( Chamchod, S; Kongwattanakul, S; Nantajit, D; Petchann, N; Petroch, P; Pitiporn, S; Thanthong, S; Tungfung, S, 2022) |
| "Data from 23 patients with head and neck cancer who underwent FDG-PET/CT and panoramic and periapical radiography in close succession before first-line radiotherapy and/or chemotherapy were included in this exploratory retrospective study." | ( Balermpas, P; Bichsel, D; Giacomelli-Hiestand, B; Hüllner, M; Schwaninger, DR; Stadlinger, B; Stutzmann, NS; Valdec, S, 2022) |
| "Treatment for head and neck cancer (HNC) such as radiotherapy (RT) can lead to numerous acute and chronic head and neck sequelae, including dental caries." | ( Brennan, MT; Elting, LS; Helgeson, ES; Lalla, RV; Lin, A; Patton, LL; Schmidt, BL; Sollecito, TP; Treister, NS, 2023) |
| "In a prospective head and neck cancer study, MRI data of 29 patients has been acquired at 3 different time points during radiation treatment." | ( Bielak, L; Bock, M; Grosu, AL; Henrik Nicolay, N; Lottner, T; Ludwig, U; Rühle, A, 2022) |
| "Proton therapy is promising in head and neck cancers to further reduce radiation-induced side-effects, but the optimal dental management has not been defined." | ( Beddok, A; Dore, M; Drouet, J; Dutheil, P; Epstein, J; Falek, S; Herault, J; Letwin, NE; Marcy, PY; Moignier, C; Parvathaneni, U; Regmi, R; Thariat, J; Vela, A, 2022) |
| "Head and neck cancer (HNC) patients are at risk of weight change, due to inadequate nutrition intake or dehydration, when receiving radiotherapy (RT)." | ( Aly, F; Bell, K; Duncan, S; Dundas, K; Kumar, S; Lee, M; Surjan, Y; Walker, A; Wallis, A, 2022) |
| "Among 52 patients with head and neck cancer treated with postoperative radiochemotherapy, 18 patients received cetuximab potentiation due to ineligibility for cisplatin." | ( Brenet, E; Gaultier, V; Marchand-Crety, C; Marques, O, 2023) |
| "Head and neck cancers are the third most common cancers treated with radiation in Ethiopia." | ( Fekadu, A; Incrocci, L; Jemal, A; Kantelhardt, EJ; Rick, TJ; Tigeneh, W, 2022) |
| "Majority of patients with head and neck cancers seen in Ethiopia presented at advanced stage of disease, received cobalt radiotherapy, and had protracted treatment initiation." | ( Fekadu, A; Incrocci, L; Jemal, A; Kantelhardt, EJ; Rick, TJ; Tigeneh, W, 2022) |
| "Radiotherapy of locally advanced head and neck cancer represents a major clinical challenge." | ( Barilíková, G; Dubinský, P; Jeremic, B; Matula, P; Nadzonová, D; Švajdová, M; Vojtek, V, 2022) |
| "The majority of tobacco-related head and neck cancer patients required nicotine de-addiction treatment." | ( Ganesan, S; Nagappa, B; Pandjatcharam, J; Sakthivel, M; Sekhar Kar, S; Thulasingam, M, 2022) |
| "Patients treated for head and neck cancer are chronic opioid users to manage their post-treatment pain, which may entail an increased risk of addiction and overdose." | ( Boden, A; Bourgouin, M; Caunes-Hilary, N; Fabre, A; Filleron, T; Lodin, S; Lusque, A; Mauries, V; Moreau, C; Mounier, M; Poublanc, M, 2022) |
| "Patients treated for head and neck cancer are chronic opioid users to manage their post-treatment pain, which may entail an increased risk of addiction and overdose." | ( Boden, A; Bourgouin, M; Caunes-Hilary, N; Fabre, A; Filleron, T; Lodin, S; Lusque, A; Mauries, V; Moreau, C; Mounier, M; Poublanc, M, 2022) |
| "Cisplatin-treated patients with head and neck cancer were included." | ( Cursino, MA; de Godoy Torso, N; Moriel, P; Pincinato, EC; Quintanilha, JCF; Visacri, MB, 2022) |
| "Head and neck cancer patients receiving definite chemoradiotherapy with weekly 40 mg/m2 body surface area (BSA) cisplatin or paclitaxel 45 mg/m2 BSA and carboplatin AUC2 were consecutively included and retrospectively analysed." | ( Becker, JN; Bruns, F; Christiansen, H; Hermann, R; Sonnhoff, M; Wichmann, J, 2023) |
| "Head and neck cancer patients enrolled in an ototoxicity monitoring program demonstrate moderately high follow-up rates for at least one post-treatment audiogram." | ( Adkins, DR; Collopy, C; Jackson, RS; Lee, DS; Mazul, AL; McClannahan, KS; Oppelt, P; Ortmann, AJ; Paniello, RC; Pipkorn, P; Puram, SV; Rich, JT; Thorstad, WL; Travis, EY; Wick, CC; Wong, SK; Zevallos, JP, 2023) |
| "Curative intent treatment of head and neck cancer (HNC) is frequently radiation therapy over 7 weeks with concurrent chemotherapy." | ( Eckstein, J; Frank, D; Ghaly, M; Herman, J; Koffler, D; Kohn, N; Martins-Welch, D; Parashar, B; Potters, L; Seetharamu, N; Sullivan, K, 2023) |
| "Fifty-three head and neck cancer patients receiving cisplatin-based chemotherapy with oral aprepitant were enrolled." | ( Hosokawa, S; Kawakami, J; Naito, T; Shibata, K; Suzuki, Y, 2023) |
| "Head and neck cancers (HNC), the sixth most common malignancy worldwide, require a multimodal approach, especially in advanced stages and cancer specific treatment is often associated with therapeutic failure and severe toxicities even if it is delivered according to current standards." | ( Badulescu, F; Mirestean, CC; Stan, MC, 2023) |
| "In the treatment of head and neck cancer, cisplatin is often used as a therapeutic agent; however, its efficacy is limited and it can cause renal dysfunction as an adverse effect." | ( Fujimoto, Y; Inukai, D; Ogawa, T; Okamoto, H; Sano, R; Shimada, A; Suzuki, S; Ueda, H; Ueda, R; Yamanaka, S; Yoshikawa, K, 2023) |
| "Patients with head and neck cancer have a substantial risk of chronic opioid dependence following surgery due to pain and psychosocial consequences from both the disease process and its treatments." | ( Colloca, L; Fakhry, C; Khan, Z; Tan, M; Trakimas, DR; Vosler, PS, 2023) |
| "20 complex cases of head and neck cancer previously treated with conventional CIRT were retrospectively planned using horizontal-port-only treatment incorporating non-coplanar treatment angles to achieve greater degrees of freedom." | ( Ebner, D; Furuichi, W; Koto, M; Mori, S, 2023) |
| "Head and neck cancer (HNC) therapy is limited; therefore, new solutions are increasingly being sought among flavonoids, which exhibit numerous biological properties, including potential anticancer activity." | ( Dziedzic, A; Kadela-Tomanek, M; Krzykawski, K; Kubina, R; Madej, M; Sokal, A, 2023) |
| "Ionizing radiation, commonly used for head and neck cancer treatment, typically damages the salivary glands, resulting in hyposalivation." | ( Andreadis, ST; Baker, OJ; Dos Santos, HT; Lei, P; Maslow, F; Nam, K; Samuel, RZ; Small, T, 2023) |